Enzyme that catalyzes a peptide-forming reaction from a carboxy component and an amine component, microbe producing the same, and a method of producing a dipeptide using the enzyme or microbe

ABSTRACT

DNA and recombinant DNA that encode a peptide-forming enzyme, a method for producing a peptide-forming enzyme, and a method for producing a dipeptide are disclosed. A method for producing a dipeptide includes producing a dipeptide from a carboxy component and an amine component by using a culture of a microbe belonging to the genus  Sphingobacterium  and having the ability to form the dipeptide from the carboxy component and the amine component, a microbial cell separated from the culture, treated microbial cell product of the microbe or a peptide-forming enzyme derived from the microbe.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a divisional application of U.S. Ser. No.13/611,827, filed Sep. 12, 2012, which is a divisional application ofU.S. Ser. No. 13/211,834, filed Aug. 17, 2011, which is a divisionalapplication of U.S. Ser. No. 12/729,656, filed Mar. 23, 2010, which is adivisional application of U.S. Ser. No. 11/841,151, filed on Aug. 20,2007, which is a divisional application of U.S. Ser. No. 10/855,533,filed on May 28, 2004, which is a continuation of PCT/JP03/09468 filedon Jul. 25, 2003, which claims priority to JP 2003-16765, filed on Jan.24, 2003, and to JP 2002-218957, filed on Jul. 26, 2002.

TECHNICAL FIELD

The present invention relates to a novel enzyme that can form a peptideeasily, at high yield and inexpensively without going through a complexsynthetic method. More particularly, the present invention relates to anovel enzyme that catalyzes a peptide-forming reaction from a carboxycomponent and an amine component, to a microbe that produces the enzyme,and to a method for producing dipeptide using this enzyme or microbe.

BACKGROUND ART

Peptides are used in the fields of pharmaceuticals, foods and variousother fields. For example, since L-alanyl-L-glutamine has higherstability and water-solubility than L-glutamine, it is widely used as acomponent of fluid infusion and serum-free media.

Chemical synthesis methods, which have been known as methods forproducing peptides, are not always easy. Known examples of such methodsinclude a method that uses N-benzyloxycarbonylalanine (hereinafter,“Z-alanine”) and protected L-glutamine (see Bull. Chem. Soc. Jpn., 34,739 (1961), Bull. Chem. Soc. Jpn., 35, 1966 (1962)), a method that usesZ-alanine and protected L-glutamic acid-γ-methyl ester (see Bull. Chem.Soc. Jpn., 37, 200 (1964)), a method that uses Z-alanine ester andunprotected glutamic acid (see Japanese Patent Application Laid-openPublication No. H1-96194), a method that involves synthesis of anN-(2-substituted)-propionyl glutamine derivative as an intermediate froma 2-substituted-propionyl halide as a raw material (see PatentApplication Laid-open Publication No. H6-234715).

However, since all these methods require the introduction andelimination of protecting groups or the use of an optically activeintermediate, they are not considered to be adequately satisfactory interms of their industrial advantages.

On the other hand, widely known examples of typical peptide productionmethods using enzymes consist of a condensation reaction that uses anN-protected and C-unprotected carboxy component and an N-unprotected,C-protected amine component (hereinafter, “Reaction 1”), and asubstitution reaction that uses an N-protected, C-protected carboxycomponent and an N-unprotected, C-protected amine component(hereinafter, “Reaction 2”). An example of Reaction 1 is a method forproducing Z-aspartylphenylalanine methyl ester from Z-aspartic acid andphenylalanine methyl ester (see Japanese Patent Application Laid-openPublication No. S53-92729), while an example of Reaction 2 is a methodfor producing acetylphenylalanylleucine amide from acetylphenylalanineethyl ester and leucine amide (see Biochemical J., 163, 531 (1977)).There have been reported very few research examples of method that usesan N-unprotected, C-protected carboxy component. An example of asubstitution reaction that uses an N-unprotected, C-protected carboxycomponent and an N-unprotected, C-protected amine component(hereinafter, “Reaction 3”) is described in International PatentPublication WO 90/01555. For example, a method for producingarginylleucine amide from arginine ethyl ester and leucine amide may bementioned of. Examples of substitution reactions that use anN-unprotected, C-protected carboxy component and an N-unprotected,C-unprotected amine component (hereinafter, “Reaction 4”) are describedin European Patent Publication EP 278787A1 and European PatentPublication EP 359399B1. For example, a method for producingtyrosylalanine from tyrosine ethyl ester and alanine may be mentionedof.

DISCLOSURE OF THE INVENTION

The most inexpensive production method among the aforementioned methodsof Reactions 1 to 4 naturally falls within the class of Reaction 4,which involves the fewest protecting groups.

However, the example of Reaction 4 of the prior art (see European PatentPublication EP 278787A1) had the following major problems: (1) extremelyslow rate of peptide production, (2) low peptide production yield, (3)the peptides that can be produced are limited to those that containamino acids with comparatively high hydrophobicity, (4) the amount ofenzyme added is extremely large, and (5) comparatively expensivecarboxypeptidase preparations derived from molds, yeasts or plants arerequired. In the Reaction 4, there is no method known whatsoever thatuses an enzyme derived from bacteria or yeasts other than the genusSaccharomyces, and there are no known method for producingalanylglutamine and other peptides that are highly hydrophilic. Inconsideration of this background, there is a need to develop anindustrially inexpensive method for producing these peptides.

It is an object of the present invention to provide a novel enzyme thatcan form a peptide easily, at high yield and inexpensively without goingthrough a complex synthesis method. More particularly, an object of thepresent invention is to provide a novel enzyme that catalyzes apeptide-forming reaction from a carboxy component and an aminecomponent, a microbe that produces the enzyme, and a method forinexpensively producing a peptide using this enzyme or microbe.

As a result of conducting extensive research in consideration of theabove object, the inventors of the present invention have found a novelenzyme that efficiently forms a peptide from newly discovered bacteriabelonging to the genus Empedobacter, etc. and determined the sequence ofthis enzyme gene, thereby leading to completion of the presentinvention.

Namely, the present invention is as described below.

[1] A DNA encoding a protein selected from the group consisting of (A),(C), (E), (G), (I), (K), (M), (O), (Q), (S), (U), and (W), wherein theprotein has an amino acid sequence defined as follows:

(A) an amino acid sequence consisting of amino acid residue numbers 23to 616 of SEQ ID NO:6,

(C) an amino acid sequence consisting of amino acid residue numbers 21to 619 of SEQ ID NO:12,

(E) an amino acid sequence consisting of amino acid residue numbers 23to 625 of SEQ ID NO:18,

(G) an amino acid sequence consisting of amino acid residue numbers 23to 645 of SEQ ID NO:23,

(I) an amino acid sequence consisting of amino acid residue numbers 26to 620 of SEQ ID NO:25,

(K) an amino acid sequence consisting of amino acid residue numbers 18to 644 of SEQ ID NO:27,

(M) an amino acid sequence consisting of SEQ ID NO:6,

(O) an amino acid sequence consisting of SEQ ID NO:12,

(Q) an amino acid sequence consisting of SEQ ID NO:18,

(S) an amino acid sequence consisting of SEQ ID NO:23,

(U) an amino acid sequence consisting of SEQ ID NO:25, or

(W) an amino acid sequence consisting of SEQ ID NO:27,

[2] A recombinant DNA including the DNA according to [1] above.[3] A transformed cell including the recombinant DNA according to [2]above.[4] A method for producing a peptide-forming enzyme including:

culturing the transformed cell according to [3] above in a medium for atime and under conditions suitable to produce the peptide-formingenzyme, and

accumulating the peptide-forming enzyme in the medium and/or transformedcell.

[5] A method for producing a dipeptide including:

culturing the transformed cell according to [3] in a medium for a timeand under conditions suitable to produce a peptide-forming enzyme in aculture, and

mixing the culture with a carboxy component and an amine component tosynthesize a dipeptide by enzymatic catalysis facilitated by apeptide-forming enzyme encoded by the DNA.

[6] The method for producing a dipeptide according to [5] above, whereinthe cell is a microbe belonging to the genus Sphingobacterium that hasan ability to form the dipeptide from the carboxy component and theamine component.[7] The method for producing a dipeptide according to [6] above, whereinthe cell is separated from the culture.[8] The method for producing a dipeptide according to [6] above, whereinthe cell is a treated microbial cell product of the microbe.[9] A DNA encoding a protein selected from the group consisting of (B),(D), (F), (H), (J), (L), (N), (P), (R), (T), (V), and (X), wherein theprotein has an amino acid sequence defined as follows:

(B) an amino acid sequence including substitution, deletion, insertion,addition, and/or inversion of one or a plurality of amino acids in aminoacid residue numbers 23 to 616 of SEQ ID NO:6, and has at least 50% ofthe peptide-forming activity of a protein corresponding to unmutatedamino acid residue numbers 23 to 616 of SEQ ID NO:6 at 50° C. and a pHof 8,

(D) an amino acid sequence including substitution, deletion, insertion,addition, and/or inversion of one or a plurality of amino acids in aminoacid residue numbers 21 to 619 of SEQ ID NO:12, and has at least 50% ofthe peptide-forming activity of a protein corresponding to unmutatedamino acid residue numbers 21 to 619 of SEQ ID NO:12 at 50° C. and a pHof 8,

(F) an amino acid sequence including substitution, deletion, insertion,addition, and/or inversion of one or a plurality of amino acids in aminoacid residue numbers 23 to 625 of SEQ ID NO:18, and has at least 50% ofthe peptide-forming activity of a protein corresponding to unmutatedamino acid residue numbers 23 to 625 of SEQ ID NO:18 at 50° C. and a pHof 8,

(H) an amino acid sequence including substitution, deletion, insertion,addition, and/or inversion of one or a plurality of amino acids in aminoacid residue numbers 23 to 645 of SEQ ID NO:23, and has at least 50% ofthe peptide-forming activity of a protein corresponding to unmutatedamino acid residue numbers 23 to 645 of SEQ ID NO:23 at 50° C. and a pHof 8,

(J) an amino acid sequence including substitution, deletion, insertion,addition, and/or inversion of one or a plurality of amino acids in aminoacid residue numbers 26 to 620 of SEQ ID NO:25, and has at least 50% ofthe peptide-forming activity of a protein corresponding to unmutatedamino acid residue numbers 26 to 620 of SEQ ID NO:25 at 50° C. and a pHof 8,

(L) an amino acid sequence including substitution, deletion, insertion,addition, and/or inversion of one or a plurality of amino acids in aminoacid residue numbers 18 to 644 of SEQ ID NO:27, and has at least 50% ofthe peptide-forming activity of a protein corresponding to unmutatedamino acid residue numbers 18 to 644 of SEQ ID NO:27 at 50° C. and a pHof 8,

(N) a mature protein region, having an amino acid sequence includingsubstitution, deletion, insertion, addition, and/or inversion of one ora plurality of amino acids in an amino acid sequence consisting of SEQID NO:6, and has at least 50% of the peptide-forming activity of aprotein corresponding to unmutated SEQ ID NO:6 at 50° C. and a pH of 8,

(P) a mature protein region, having an amino acid sequence includingsubstitution, deletion, insertion, addition, and/or inversion of one ora plurality of amino acids in an amino acid sequence consisting of SEQID NO:12, and has at least 50% of the peptide-forming activity of aprotein corresponding to unmutated SEQ ID NO:12 at 50° C. and a pH of 8,

(R) a mature protein region, having an amino acid sequence includingsubstitution, deletion, insertion, addition, and/or inversion of one ora plurality of amino acids in an amino acid sequence consisting of SEQID NO:18, and has at least 50% of the peptide-forming activity of aprotein corresponding to unmutated SEQ ID NO:18 at 50° C. and a pH of 8,

(T) a mature protein region, having an amino acid sequence includingsubstitution, deletion, insertion, addition, and/or inversion of one ora plurality of amino acids in an amino acid sequence consisting of SEQID NO:23, and has at least 50% of the peptide-forming activity of aprotein corresponding to unmutated SEQ ID NO:23 at 50° C. and a pH of 8,

(V) a mature protein region, having an amino acid sequence includingsubstitution, deletion, insertion, addition, and/or inversion of one ora plurality of amino acids in an amino acid sequence consisting of SEQID NO:25, and has at least 50% of the peptide-forming activity of aprotein corresponding to unmutated SEQ ID NO:25 at 50° C. and a pH of 8,or

(X) a mature protein region, having an amino acid sequence includingsubstitution, deletion, insertion, addition, and/or inversion of one ora plurality of amino acids in an amino acid sequence consisting of SEQID NO:27, and has at least 50% of the peptide-forming activity of aprotein corresponding to unmutated SEQ ID NO:27 at 50° C. and a pH of 8.

[10] The DNA according to [9] above, wherein the plurality is 2 to 50amino acid residues.[11] A recombinant DNA including the DNA according to [9] above.[12] A transformed cell including the recombinant DNA according to [11]above.[13] A method for producing a peptide-forming enzyme including:

culturing the transformed cell according to [12] above, in a medium fora time and under conditions suitable to produce the peptide-formingenzyme, and

accumulating the peptide-forming enzyme in the medium and/or transformedcell.

[14] A method for producing a dipeptide including:

culturing the transformed cell according to [12] above in a medium for atime and under conditions suitable to produce a peptide-forming enzymein a culture, and

mixing the culture with a carboxy component and an amine component tosynthesize a dipeptide by enzymatic catalysis facilitated by apeptide-forming enzyme encoded by the DNA.

[15] The method for producing a dipeptide according to [14] above,wherein the cell is a microbe belonging to the genus Sphingobacteriumthat has an ability to form the dipeptide from the carboxy component andthe amine component.[16] The method for producing a dipeptide according to [15] above,wherein the cell is separated from the culture.[17] The method for producing a dipeptide according to [15] above,wherein the cell is a treated microbial cell product of the microbe.[18] A DNA selected from the group consisting of (a), (c), (e), (g),(i), (k), (m), (o), (q), (s), (u), and (w), wherein the DNA has a basesequence defined as follows:

(a) a base sequence consisting of base numbers 127 to 1908 of SEQ IDNO:5,

(c) a base sequence consisting of base numbers 121 to 1917 of SEQ IDNO:11,

(e) a base sequence consisting of base numbers 127 to 1935 of SEQ IDNO:17,

(g) a base sequence consisting of base numbers 127 to 1995 of SEQ IDNO:22,

(i) a base sequence consisting of base numbers 104 to 1888 of SEQ IDNO:24,

(k) a base sequence consisting of base numbers 112 to 1992 of SEQ IDNO:26,

(m) a base sequence consisting of base numbers 61 to 1908 of SEQ IDNO:5,

(o) a base sequence consisting of base numbers 61 to 1917 of SEQ IDNO:11,

(q) a base sequence consisting of base numbers 61 to 1935 of SEQ IDNO:17,

(s) a base sequence consisting of base numbers 61 to 1995 of SEQ IDNO:22,

(u) a base sequence consisting of base numbers 29 to 1888 of SEQ IDNO:24, or

(w) a base sequence consisting of base numbers 61 to 1992 of SEQ IDNO:26.

[19] A recombinant DNA including the DNA according to [18] above.[20] A transformed cell including the recombinant DNA according to [19]above.[21] A method for producing a peptide-forming enzyme including:

culturing the transformed cell according to [20] in a medium for a timeand under conditions suitable to produce the peptide-forming enzyme, and

accumulating the peptide-forming enzyme in the medium and/or transformedcell.

[22] A method for producing a dipeptide including:

culturing the transformed cell according to [20] in a medium for a timeand under conditions suitable to produce a peptide-forming enzyme in aculture, and

mixing the culture with a carboxy component and an amine component tosynthesize a dipeptide by enzymatic catalysis facilitated by apeptide-forming enzyme encoded by the DNA.

[23] The method for producing a dipeptide according to [22] above,wherein the cell is a microbe belonging to the genus Sphingobacteriumthat has an ability to form the dipeptide from the carboxy component andthe amine component.[24] The method for producing a dipeptide according to [23], wherein thecell is separated from the culture.[25] The method for producing a dipeptide according to [23], wherein thecell is a treated microbial cell product of the microbe.[26] A DNA selected from the group consisting of (b), (d), (f), (h),(j), (l), (n), (p), (r), (t), (v), and (x), wherein the DNA has a basesequence defined as follows:

(b) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 127 to 1908 of SEQ ID NO:5, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 127 to 1908 of SEQ IDNO:5,

(d) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 121 to 1917 of SEQ ID NO:11, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 121 to 1917 of SEQ IDNO:11,

(f) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 127 to 1935 of SEQ ID NO:17, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 127 to 1935 of SEQ IDNO:17,

(h) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 127 to 1995 of SEQ ID NO:22, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 127 to 1995 of SEQ IDNO:22,

(j) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 104 to 1888 of SEQ ID NO:24, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 104 to 1888 of SEQ IDNO:24,

(l) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 112 to 1992 of SEQ ID NO:26, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 112 to 1992 of SEQ IDNO:26,

(n) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 61 to 1908 of SEQ ID NO:5, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 61 to 1908 of SEQ IDNO:5,

(p) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 61 to 1917 of SEQ ID NO:11, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 61 to 1917 of SEQ IDNO:11,

(r) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 61 to 1935 of SEQ ID NO:17, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 61 to 1935 of SEQ IDNO:17,

(t) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 61 to 1995 of SEQ ID NO:22, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 61 to 1995 of SEQ IDNO:22,

(v) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 29 to 1888 of SEQ ID NO:24, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 29 to 1888 of SEQ IDNO:24, or

(x) a base sequence that hybridizes under stringent conditions with aDNA having a base sequence complementary to a base sequence consistingof base numbers 61 to 1992 of SEQ ID NO:26, and encodes a protein thathas at least 50% of the peptide-forming activity at 50° C. and a pH of 8of a protein encoded by unmutated base numbers 61 to 1992 of SEQ IDNO:26.

[27] A recombinant DNA including the DNA according to [26] above.[28] A transformed cell including the recombinant DNA according to [26]above.[29] A method for producing a peptide-forming enzyme including:

culturing the transformed cell according to [28] in a medium for a timeand under conditions suitable to produce the peptide-forming enzyme, and

accumulating the peptide-forming enzyme in the medium and/or transformedcell.

[30] A method for producing a dipeptide including:

culturing the transformed cell according to [28] in a medium for a timeand under conditions suitable to produce a peptide-forming enzyme in aculture, and

mixing the culture with a carboxy component and an amine component tosynthesize a dipeptide by enzymatic catalysis facilitated by apeptide-forming enzyme encoded by the DNA.

[31] The method for producing a dipeptide according to [30] above,wherein the cell is a microbe belonging to the genus Sphingobacteriumthat has an ability to form the dipeptide from the carboxy component andthe amine component.[32] The method for producing a dipeptide according to [31] above,wherein the cell is separated from the culture.[33] The method for producing a dipeptide according to [31] above,wherein the cell is a treated microbial cell product of the microbe.[34] The DNA according to [26] above, wherein stringent conditions areconditions under which washing is carried out at 60° C. at a saltconcentration equivalent to 1×SSC and 0.1% SDS.[35] A recombinant DNA including the DNA according to [34].[36] A transformed cell including the recombinant DNA according to [35].[37] A method for producing a peptide-forming enzyme including:

culturing the transformed cell according to [36] in a medium fro a timeand under conditions suitable to produce the peptide-forming enzyme, and

accumulating the peptide-forming enzyme in the medium and/or transformedcell.

[38] A method for producing a dipeptide including:

culturing the transformed cell according to [36] in a medium and underconditions suitable to produce a dipeptide-forming enzyme in a culture,and

mixing the culture with a carboxy component and an amine component tosynthesize a dipeptide by enzymatic catalysis facilitated by apeptide-forming enzyme encoded by the DNA.

Furthermore, the amino acid sequence described in SEQ ID NO: 6 isspecified by the DNA described in SEQ ID NO: 5 of the Sequence Listing.The amino acid sequence described in SEQ ID NO: 12 is specified by theDNA described in SEQ ID NO: 11. The amino acid sequence described in SEQID NO: 18 is specified by the DNA described in SEQ ID NO: 17. The aminoacid sequence described in SEQ ID NO: 23 is specified by the DNAdescribed in SEQ ID NO: 22. The amino acid sequence described in SEQ IDNO: 25 is specified by the DNA described in SEQ ID NO: 24. The aminoacid sequence described in SEQ ID NO: 27 is specified by the DNAdescribed in SEQ ID NO: 26.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph illustrating the optimum pH of the enzyme ofEmpedobacter of the present invention;

FIG. 2 is a graph illustrating the optimum temperature of the enzyme ofEmpedobacter of the present invention;

FIG. 3 is a graph illustrating the time course of L-alanyl-L-glutamineproduction from L-alanine methyl ester and L-glutamine; and

FIG. 4 is a bar graph illustrating the amount of enzyme present in acytoplasm fraction (Cy) and a periplasm fraction (Pe).

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the novel dipeptide-forming enzyme gene of the presentinvention and the dipeptide-forming enzyme that is the product of thatgene.

(1) Microbes Harboring the DNA of the Present Invention

The DNA of the present invention encodes a protein having the ability toform a peptide from a carboxy component and an amine component. In thepresent specification, a carboxy component refers to a component thatprovides a carbonyl site (CO) in a peptide bond (—CONH—), while an aminecomponent refers to a component that provides an amino site (NH) in apeptide bond. In addition, in the present specification, unlessotherwise indicated specifically, the term “peptide” when used alonerefers to a polymer having at least one peptide bond. In addition, inthe present specification, “dipeptide” refers to a peptide having onepeptide bond.

Examples of microbes harboring the DNA of the present invention includebacteria belonging to the genus Empedobacter, genus Sphingobacterium,genus Pedobacter, genus Taxeobacter, genus Cyclobacterium or genusPsycloserpens, while more specific examples thereof include Empedobacterbrevis strain ATCC 14234 (strain FERM P-18545, strain FERM BP-8113),Sphingobacterium sp. strain FERM BP-8124, Pedobacter heparinus strainIFO 12017, Taxeobacter gelupurpurascens strain DSMZ 11116,Cyclobacterium marinum strain ATCC 25205 and Psycloserpens burtonensisstrain ATCC 700359. Empedobacter brevis strain ATCC 14234 (strain FERMP-18545, strain FERM BP-8113), Sphingobacterium sp. strain FERM BP-8124,Pedobacter heparinus strain IFO 12017, Taxeobacter gelupurpurascensstrain DSMZ 11116, Cyclobacterium marinum strain ATCC 25205 andPsycloserpens burtonensis strain ATCC 700359 are microbes that wereselected as a result of searching by the inventors of the presentinvention for microbes that produce an enzyme which forms a peptide froma carboxy component and an amine component at high yield.

Among the aforementioned strains of microbes, those microbes describedwith FERM numbers have been deposited at the independent administrativecorporation, National Institute of Advanced Industrial Science andTechnology, International Patent Organism Depository (Chuo Dai-6, 1-1Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan), and can be furnishedby referring to each number.

Among the aforementioned strains of microbes, those microbes describedwith ATCC numbers have been deposited at the American Type CultureCollection (P.O. Box 1549, Manassas, Va. 20110, the United States ofAmerica), and can be furnished by referring to each number.

Among the aforementioned strains of microbes, those microbes describedwith IFO numbers have been deposited at the Institute of Fermentation,Osaka (2-17-85 Jusanbon-cho, Yodogawa-ku, Osaka-shi, Japan), and can befurnished by referring to each number.

Among the aforementioned strains of microbes, those microbes describedwith NBRC numbers have been deposited at the NITE Biological ResourceCenter of the National Institute of Technology and Evaluation (5-8Kazusa-Kamaashi 2-Chome, Kisarazu-shi, Chiba-ken, Japan), and can befurnished by referring to each number.

Among the aforementioned strains of microbes, those microbes describedwith DSMZ numbers have been deposited at the Deutche Sammlung vonMikroorganismen and Zellkulturen GmbH (German Collection of Microbes andCell Cultures) (Mascheroder Weg 1b, 38124 Braunschweig, Germany), andcan be furnished by referring to each number.

Empedobacter brevis strain ATCC 14234 (strain FERM P-18545, strain FERMBP-8113) was deposited at the International Patent Organism Depositoryof the independent administrative corporation, National Institute ofAdvanced Industrial Science and Technology (Chuo Dai-6, 1-1 Higashi1-Chome, Tsukuba-shi, Ibaraki-ken, Japan) on Oct. 1, 2001 and assignedthe deposit number of FERM P-18545. Control of this organism wassubsequently transferred to deposition under the provisions of theBudapest Treaty at the International Patent Organism Depository of theindependent administrative corporation, National Institute of AdvancedIndustrial Science and Technology on Jul. 8, 2002 and was assigned thedeposit number of FERM BP-8113 (indication of microbe: Empedobacterbrevis strain AJ 13933).

Sphingobacterium sp. strain AJ 110003 was deposited at the InternationalPatent Organism Depository of the independent administrativecorporation, National Institute of Advanced Industrial Science andTechnology on Jul. 22, 2002, and was assigned the deposit number of FERMBP-8124. Note that the strain AJ 110003 (FERM BP-8124) was identified tobe the aforementioned Sphingobacterium sp. by the identificationexperiment described below. The strain FERM BP-8124 is a Gram-negativerod (0.7 to 0.8×1.5 to 2.0 μm) that forms spores and is not motile. Itscolonies are round with a completely smooth border, contain lowprotrusions and have a glossy, light yellow color. The organism grows at30° C. and is catalase positive, oxidase positive and negative for theOF test (glucose), and was identified as a bacterium belonging to thegenus Sphingobacterium based on these properties. Moreover, because ofthe properties that it is negative for nitrate reduction, negative forindole production, negative for acid production from glucose, argininedihydrolase negative, urease positive, esculin hydrolysis positive,gelatin hydrolysis negative, β-galactosidase positive, glucoseassimilation positive, L-arabinose assimilation negative, D-mannoseassimilation positive, D-mannitol assimilation negative,N-acetyl-D-glucosamine assimilation positive, maltose assimilationpositive, potassium gluconate assimilation negative, n-capric acidassimilation negative, adipic acid assimilation negative, dl-malic acidassimilation negative, sodium citrate assimilation negative, phenylacetate assimilation negative and cytochrome oxidase positive, it wasdetermined to have properties that are similar to those ofSphingobacterium multivorum or Sphingobacterium spiritivorum. Moreover,although results of analyses on the homology of the base sequence of the16S rRNA gene indicate the highest degree of homology withSphingobacterium multivorum (98.8%), there was no strain with which thebacterial strain matched completely. Accordingly, this bacterial strainwas therefore identified as Sphingobacterium sp.

(2) Microbe Culturing

In order to obtain microbial cells of microbes having the DNA of thepresent invention, the microbes can be cultured and grown in a suitablemedium. There is no particular restriction on the medium used for thispurpose so far as it allows the microbes to grow. This medium may be anordinary medium containing ordinary carbon sources, nitrogen sources,phosphorus sources, sulfur sources, inorganic ions, and organic nutrientsources as necessary.

For example, any carbon source may be used so far as the microbes canutilize it. Specific examples of the carbon source that can be usedinclude sugars such as glucose, fructose, maltose and amylose, alcoholssuch as sorbitol, ethanol and glycerol, organic acids such as fumaricacid, citric acid, acetic acid and propionic acid and their salts,hydrocarbons such as paraffin as well as mixtures thereof.

Examples of nitrogen sources that can be used include ammonium salts ofinorganic acids such as ammonium sulfate and ammonium chloride, ammoniumsalts of organic acids such as ammonium fumarate and ammonium citrate,nitrates such as sodium nitrate and potassium nitrate, organic nitrogencompounds such as peptones, yeast extract, meat extract and corn steepliquor as well as mixtures thereof.

In addition, nutrient sources used in ordinary media, such as inorganicsalts, trace metal salts and vitamins, can also be suitably mixed andused.

There is no particular restriction on culturing conditions, andculturing can be carried out, for example, for about 12 to about 48hours while properly controlling the pH and temperature within a pHrange of 5 to 8 and a temperature range of 15 to 40° C., respectively,under aerobic conditions.

(3) Purification of Enzyme

The DNA of the present invention encodes a peptide-forming enzyme. Thispeptide-forming enzyme can be purified from bacteria belonging to, forexample, the genus Empedobacter. A method for isolating and purifying apeptide-forming enzyme from Empedobacter brevis is explained as anexample of purification of the enzyme.

First, a microbial cell extract is prepared from the microbial cells ofEmpedobacter brevis, for example, the strain FERM BP-8113 (Depositaryinstitution: the independent administrative corporation, NationalInstitute of Advanced Industrial Science and Technology, InternationalPatent Organism Depositary, Address of depositary institution: ChuoDai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan,International deposit transfer date: Jul. 8, 2002) by disrupting thecells using a physical method such as ultrasonic disruption or anenzymatic method using a cell wall-dissolving enzyme and removing theinsoluble fraction by centrifugation and so forth. The peptide-formingenzyme can then be purified by fractionating the microbial cell extractsolution obtained in the above manner by combining ordinary proteinpurification methods such as anion exchange chromatography, cationexchange chromatography or gel filtration chromatography.

An example of a carrier for use in anion exchange chromatography isQ-Sepharose HP (manufactured by Amersham). The enzyme is recovered inthe non-adsorbed fraction under conditions of pH 8.5 when the cellextract containing the enzyme is allowed to pass through a column packedwith the carrier.

An example of a carrier for use in cation exchange chromatography isMonoS HR (manufactured by Amersham). After adsorbing the enzyme onto thecolumn by allowing the cell extract containing the enzyme to passthrough a column packed with the carrier and then washing the column,the enzyme is eluted with a buffer solution having a high saltconcentration. At that time, the salt concentration may be sequentiallyincreased or a concentration gradient may be applied. For example, inthe case of using MonoS HR, the enzyme adsorbed onto the column iseluted with NaCl of about 0.2 to about 0.5 M.

The enzyme purified in the manner described above can then be furtheruniformly purified by gel filtration chromatography and so forth. Anexample of the carrier for use in gel filtration chromatography isSephadex 200pg (manufactured by Amersham).

In the aforementioned purification procedure, the fraction containingthe enzyme can be verified by assaying the peptide-forming activity ofeach fraction according to the method indicated in the examples to bedescribed later. The internal amino acid sequence of the enzyme purifiedin the manner described above is shown in SEQ ID NO: 1 and SEQ ID NO: 2of the Sequence Listing.

(4) DNA Of the Present Invention and Transformants (4-1) DNA Of thePresent Invention

A DNA of the present invention having the base sequence consisting ofbase numbers 61 to 1908 described in SEQ ID NO: 5 was isolated fromEmpedobacter brevis strain FERM BP-8113 (Depositary institution: theindependent administrative corporation, National Institute of AdvancedIndustrial Science and Technology, International Patent OrganismDepositary, Address of depositary institution: Chuo Dai-6, 1-1 Higashi1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, International deposit transferdate: Jul. 8, 2002). The DNA consisting of bases numbers 61-1908described in SEQ ID NO: 5 is a code sequence (hereinafter, “CDS”)portion. The base sequence consisting of bases numbers 61 to 1908contains a signal sequence region and a mature protein region. Thesignal sequence region consists of bases numbers 61 to 126, while themature protein region consists of bases numbers 127 to 1908. Namely, thepresent invention provides both a peptide enzyme protein gene thatcontains a signal sequence, and a peptide enzyme protein gene in theform of a mature protein. The signal sequence contained in the sequencedescribed in SEQ ID NO: 5 is a type of leader sequence, and the mainfunction of the leader peptide encoded by this leader sequence ispresumed to be excretion from inside the cell membrane to outside thecell membrane. The protein encoded by bases numbers 127 to 1908, namelythe site excluding the leader peptide, is a mature protein, and ispresumed to exhibit a high degree of peptide-forming activity.

The DNA having a base sequence consisting of bases numbers 61 to 1917described in SEQ ID NO: 11, which is also a DNA of the presentinvention, was isolated from Sphingobacterium sp. strain FERM BP-8124(Depositary institution: the independent administrative corporation,National Institute of Advanced Industrial Science and Technology,International Patent Organism Depositary, Address of depositaryinstitution: Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken,Japan, International deposit date: Jul. 22, 2002). The DNA having a basesequence consisting of bases numbers 61 to 1917 is a code sequence (CDS)portion. The base sequence consisting of bases numbers 61 to 1917contains a signal sequence region and a mature protein region. Thesignal sequence region is a region that consists of bases numbers 61 to120, while the mature protein region is a region that consists of basesnumbers 121 to 1917. Namely, the present invention provides both a genefor a peptide enzyme protein gene that contains a signal sequence, and agene for a peptide enzyme protein gene in the form of a mature protein.The signal sequence contained in the sequence described in SEQ ID NO: 11is a kind of leader sequence. The main function of a leader peptideencoded by the leader sequence is presumed to be excretion from insidethe cell membrane to outside the cell membrane. The protein encoded bybases numbers 121 to 1917, namely the portion excluding the leaderpeptide, is a mature protein, and it is presumed to exhibit a highdegree of peptide-forming activity.

A DNA of the present invention having the base sequence consisting ofbases numbers 61 to 1935 described in SEQ ID NO: 17 was isolated fromPedobacter heparinus strain IFO 12017 (Depositary institution: Instituteof Fermentation, Osaka, Address of depositary institution: 2-17-85Jusanbon-cho, Yodogawa-ku, Osaka-shi, Japan). The DNA consisting ofbases numbers 61 to 1935 described in SEQ ID NO: 17 is a CDS portion. Asignal sequence region and a mature protein region are contained in thebase sequence consisting of bases numbers 61 to 1935. The signalsequence region consists of bases numbers 61 to 126, while the matureprotein region consists of bases numbers 127 to 1935. Namely, thepresent invention provides both a peptide enzyme protein gene thatcontains a signal sequence, and a peptide enzyme protein gene in theform of a mature protein. The signal sequence contained in the sequencedescribed in SEQ ID NO: 17 is a type of leader sequence, and the mainfunction of the leader peptide encoded by this leader sequence region ispresumed to be excretion from inside the cell membrane to outside thecell membrane. The protein encoded by bases numbers 127 to 1935, namelythe site excluding the leader peptide, is a mature protein, and ispresumed to exhibit a high degree of peptide-forming activity.

A DNA of the present invention having a base sequence consisting ofbases numbers 61 to 1995 described in SEQ ID NO: 22 was isolated fromTaxeobacter gelupurpurascens strain DSMZ 11116 (Depositary institution:Deutche Sammlung von Mikroorganismen and Zellkulturen GmbH (GermanCollection of Microbes and Cell Cultures), Address of depositaryinstitution: Mascheroder Weg 1b, 38124 Braunschweig, Germany). The DNAconsisting of bases numbers 61 to 1995 described in SEQ ID NO: 22 is aCDS portion. A signal sequence region and a mature protein region arecontained in the base sequence consisting of bases numbers 61 to 1995.The signal sequence region consists of bases numbers 61 to 126, whilethe mature protein region consists of bases numbers. 127 to 1995.Namely, the present invention provides both a peptide enzyme proteingene that contains a signal sequence, and a peptide enzyme protein genein the form of a mature protein. The signal sequence contained in thesequence described in SEQ ID NO: 22 is a type of leader sequence, andthe main function of the leader peptide encoded by this leader sequenceregion is presumed to be excretion from inside the cell membrane tooutside the cell membrane. The protein encoded by bases numbers 127 to1995, namely the site excluding the leader peptide, is a mature protein,and is presumed to exhibit a high degree of peptide-forming activity.

A DNA of the present invention having a base sequence consisting ofbases numbers 29 to 1888 described in SEQ ID NO: 24 was isolated fromCyclobacterium marinum strain ATCC 25205 (Depositary institution:American Type Culture Collection, Address of depositary institution:P.O. Box 1549, Manassas, Va. 20110, the United States of America). TheDNA consisting of bases numbers 29 to 1888 described in SEQ ID NO: 24 isa CDS portion. A signal sequence region and a mature protein region arecontained in the base sequence consisting of bases numbers 29 to 1888.The signal sequence region consists of bases numbers 29 to 103, whilethe mature protein region consists of bases numbers 104 to 1888. Namely,the present invention provides both a peptide enzyme protein gene thatcontains a signal sequence, and a peptide enzyme protein gene in theform of a mature protein. The signal sequence contained in the sequencedescribed in SEQ ID NO: 24 is a type of leader sequence, and the mainfunction of the leader peptide encoded by this leader sequence region ispresumed to be excretion from inside the cell membrane to outside thecell membrane. The protein encoded by bases numbers 104 to 1888, namelythe site excluding the leader peptide, is a mature protein, and ispresumed to exhibit a high degree of peptide-forming activity.

A DNA of the present invention having a base sequence consisting ofbases numbers 61 to 1992 described in SEQ ID NO: 26 was isolated fromPsycloserpens burtonensis strain ATCC 700359 (Depositary institution:American Type Culture Collection, Address of depositary institution:P.O. Box 1549, Manassas, Va. 20110, the United States of America). TheDNA consisting of bases numbers 61 to 1992 described in SEQ ID NO: 26 isa CDS portion. A signal sequence region and a mature protein region arecontained in the base sequence consisting of bases numbers 61 to 1992.The signal sequence region consists of bases numbers 61 to 111, whilethe mature protein region consists of bases numbers 112 to 1992. Namely,the present invention provides both a peptide enzyme protein gene thatcontains a signal sequence, and a peptide enzyme protein gene in theform of a mature protein. The signal sequence contained in the sequencedescribed in SEQ ID NO: 26 is a type of leader sequence, and the mainfunction of the leader peptide encoded by this leader sequence region ispresumed to be excretion from inside the cell membrane to outside thecell membrane. The protein encoded by bases numbers 112 to 1992, namelythe site excluding the leader peptide, is a mature protein, and ispresumed to exhibit a high degree of peptide-forming activity.

Furthermore, the various gene recombination techniques described belowcan be carried out in compliance with the descriptions in publicationssuch as Molecular Cloning, 2nd edition, Cold Spring Harbor Press (1989).

The DNA of the present invention can be obtained by polymerase chainreaction (hereinafter, “PCR”) (refer to PCR; White T. J. et al., TrendsGenet., 5, 185 (1989)) or hybridization from a chromosomal DNA or a DNAlibrary of Empedobacter brevis, Sphingobacterium sp., Pedobacterheparinus, Taxeobacter gelupurpurascens, Cyclobacterium marinum orPsycloserpens burtonensis. Primers for PCR can be designed based on theinternal amino acid sequences determined based on peptide-forming enzymepurified as explained in the aforementioned section (3). In addition,since the base sequences of peptide-forming enzyme gene (SEQ ID NO: 5,SEQ ID NO: 11, SEQ ID NO: 22, SEQ ID NO: 24 and SEQ ID NO: 26) have beenclearly determined by the present invention, primers or probes forhybridization can be designed on the basis of these base sequences, andthe gene can also be isolated using a probe. If primers having sequencescorresponding to the 5′-non-translated region and 3′-non-translatedregion are used as PCR primers, the entire length of the coding regionof the present enzyme can be amplified. For example, in amplifying theregion containing both the leader sequence and mature protein codingregion described in SEQ ID NO: 5, specifically, an example of the5′-side primer is a primer having the base sequence of the regionupstream of base number 61 in SEQ ID NO: 5, while an example of the3′-side primer is a primer having a sequence complementary to the basesequence of the region downstream of base number 1908.

Primers can be synthesized by the phosphoamidite method (see TetrahedronLetters (1981), 22, 1859) using, for example, the Model 380B DNASynthesizer manufactured by Applied Biosystems in accordance withroutine methods. The PCR reaction can be carried out, for example, inaccordance with the method specified by the supplier such as themanufacturer using the Gene Amp PCR System 9600 (manufactured byPerkin-Elmer) and the Takara LA PCR In Vitro Cloning Kit (manufacturedby Takara Shuzo).

Regardless of whether a leader sequence is contained or not, a DNAsubstantially identical to a DNA consisting of the CDS described in SEQID NO: 5 of the Sequence Listing is also included in the DNA of thepresent invention. Namely, a DNA substantially identical to the DNA ofthe present invention can be obtained by isolating a DNA that hybridizesunder stringent conditions with a DNA having a base sequencecomplementary to the CDS described in SEQ ID NO: 5 of the SequenceListing, or with a probe prepared from the same base sequence, andencodes a protein having peptide-forming activity, from DNAs encodingthe present enzyme having a mutation or cells possessing that DNA.

Regardless of whether a leader sequence is contained or not, a DNAsubstantially identical to a DNA consisting of the CDS described in SEQID NO: 11 of the Sequence Listing is also included in the DNA of thepresent invention. Namely, a DNA substantially identical to the DNA ofthe present invention can be obtained by isolating a DNA thathybridizes, under stringent conditions, with a DNA having a basesequence complementary to the CDS described in SEQ ID NO: 11 of theSequence Listing, or with a probe prepared from the same base sequence,and encodes a protein that has peptide-forming activity, from DNAsencoding the present enzyme having a mutation or cells possessing theDNA.

Regardless of whether a leader sequence is contained or not, a DNAsubstantially identical to a DNA consisting of the CDS described in SEQID NO: 17 of the Sequence Listing is also included in the DNA of thepresent invention. Namely, a DNA substantially identical to the DNA ofthe present invention can be obtained by isolating a DNA that hybridizesunder stringent conditions with a DNA having a base sequencecomplementary to the CDS described in SEQ ID NO: 17 of the SequenceListing, or with a probe prepared from the same base sequence, andencodes a protein having peptide-forming activity, from DNAs encodingthe present enzyme having a mutation or cells possessing that DNA.

Regardless of whether a leader sequence is contained or not, a DNAsubstantially identical to a DNA consisting of the CDS described in SEQID NO: 22 of the Sequence Listing is also included in the DNA of thepresent invention. Namely, a DNA substantially identical to the DNA ofthe present invention can be obtained by isolating a DNA that hybridizesunder stringent conditions with a DNA having a base sequencecomplementary to the CDS described in SEQ ID NO: 22 of the SequenceListing, or with a probe prepared from the same base sequence, andencodes a protein having peptide-forming activity, from DNAs encodingthe present enzyme having a mutation or cells possessing that DNA.

Regardless of whether a leader sequence is contained or not, a DNAsubstantially identical to a DNA consisting of the CDS described in SEQID NO: 24 of the Sequence Listing is also included in the DNA of thepresent invention. Namely, a DNA substantially identical to the DNA ofthe present invention can be obtained by isolating a DNA that hybridizesunder stringent conditions with a DNA having a base sequencecomplementary to the CDS described in SEQ ID NO: 24 of the SequenceListing, or with a probe prepared from the same base sequence, andencodes a protein having peptide-forming activity, from DNAs encodingthe present enzyme having a mutation or cells possessing that DNA.

Regardless of whether a leader sequence is contained or not, a DNAsubstantially identical to a DNA consisting of the CDS described in SEQID NO: 26 of the Sequence Listing is also included in the DNA of thepresent invention. Namely, a DNA substantially identical to the DNA ofthe present invention can be obtained by isolating a DNA that hybridizesunder stringent conditions with a DNA having a base sequencecomplementary to the CDS described in SEQ ID NO: 26 of the SequenceListing, or with a probe prepared from the same base sequence, andencodes a protein having peptide-forming activity, from DNAs encodingthe present enzyme having a mutation or cells possessing that DNA.

A probe can be produced, for example, in accordance with establishedmethods based on, for example, the base sequence described in SEQ ID NO:5 of the Sequence Listing. In addition, a method for isolating a targetDNA by using a probe to find a DNA that hybridizes with the probe mayalso be carried out in accordance with established methods. For example,a DNA probe can be produced by amplifying a base sequence cloned in aplasmid or phage vector, cleaving the base sequence desired to be usedas a probe with a restriction enzyme and then extracting the desiredbase sequence. The portion to be cleaved out can be adjusted dependingon the target DNA.

The term “under a stringent condition” as used herein refers to acondition under which a so-called specific hybrid is formed but nonon-specific hybrid is formed. It is difficult to precisely express thiscondition in numerical values. For example, mention may be made of acondition under which DNAs having high homologies, for example, 50% ormore, preferably 80% or more, more preferably 90% or more, hybridizewith each other and DNAs having lower homologies than these do nothybridize with each other, or ordinary conditions for rinse in Southernhybridization under which hybridization is performed at 60° C. in a saltconcentration corresponding to 60° C., 1×SSC and 0.1% SDS, preferably0.1×SSC and 0.1% SDS. Although the genes that hybridize under suchconditions include those genes in which stop codons have occurred atcertain locations along their sequences or which have lost activity dueto a mutation in the active center, these can be easily removed byligating them to a commercially available expression vector, expressingthem in a suitable host, and assaying the enzyme activity of theexpression product using a method to be described later.

However, in the case of a base sequence that hybridizes under stringentconditions as described above, it is preferable that the protein encodedby that base sequence retains about a half or more, preferably 80% ormore, and more preferably 90% or more, of the enzyme activity of theprotein having the amino acid sequence encoded by the original basesequence serving as the base be retained under conditions of 50° C. andpH 8. For example, when explained for on the case of, for example, abase sequence that hybridizes under stringent conditions with a DNA thathas a base sequence complementary to the base sequence consisting ofbases numbers 127 to 1908 of the base sequence described in SEQ ID NO:5, it is preferable that the protein encoded by that base sequenceretains about a half or more, preferably 80% or more, and morepreferably 90% or more, of the enzyme activity of the protein having anamino acid sequence that consists of amino acid residues numbers 23 to616 of the amino acid sequence described in SEQ ID NO: 6 underconditions of 50° C. and pH 8.

An amino acid sequence encoded by the CDS described in SEQ ID NO: 5 ofthe Sequence Listing is shown in SEQ ID NO: 6 of the Sequence Listing.An amino acid sequence encoded by the CDS described in SEQ ID NO: 11 ofthe Sequence Listing is shown in SEQ ID NO: 12 of the Sequence Listing.An amino acid sequence encoded by the CDS described in SEQ ID NO.: 17 ofthe Sequence Listing is shown in SEQ ID NO: 18 of the Sequence Listing.An amino acid sequence encoded by the CDS described in SEQ ID NO: 22 ofthe Sequence Listing is shown in SEQ ID NO: 23 of the Sequence Listing.An amino acid sequence encoded by the CDS described in SEQ ID NO: 24 ofthe Sequence Listing is shown in SEQ ID NO: 25 of the Sequence Listing.An amino acid sequence encoded by the CDS described in SEQ ID NO: 26 ofthe Sequence Listing is shown in SEQ ID NO: 27 of the Sequence Listing.

The entire amino acid sequence described in SEQ ID NO: 6 contains aleader peptide and a mature protein region, with amino acid residuesnumbers 1 to 22 constituting the leader peptide, and amino acid residuesnumbers 23 to 616 constituting the mature protein region. In addition,the entire amino acid sequence described in SEQ ID NO: 11 includes aleader peptide and a mature protein region, with amino acid residuesnumbers 1 to 20 constituting the leader peptide, and amino acid residuesnumbers 21 to 619 constituting the mature protein region.

The entire amino acid sequence described in SEQ ID NO: 18 contains aleader peptide and a mature protein region, with amino acid residuesnumbers 1 to 22 constituting the leader peptide, and amino acid residuesnumbers 23 to 625 constituting the mature protein region.

The entire amino acid sequence described in SEQ ID NO: 23 contains aleader peptide and a mature protein region, with amino acid residuesnumbers 1 to 22 constituting the leader peptide, and amino acid residuesnumbers 23 to 645 constituting the mature protein region.

The entire amino acid sequence described in SEQ ID NO: 25 contains aleader peptide and a mature protein region, with amino acid residuesnumbers 1 to 25 constituting the leader peptide, and amino acid residuesnumbers 26 to 620 constituting the mature protein region.

The entire amino acid sequence described in SEQ ID NO: 27 contains aleader peptide and a mature protein region, with amino acid residuesnumbers 1 to 17 constituting the leader peptide, and amino acid residuesnumbers 18 to 644 constituting the mature protein region.

The protein encoded by the DNA of the present invention is a protein inwhich the mature protein has peptide-forming activity, and a DNA thatencodes a protein substantially identical to a protein having the aminoacid sequence described in SEQ ID NO: 6, SEQ ID NO: 12, SEQ ID NO: 18,SEQ ID NO: 23, SEQ ID NO: 25, or SEQ ID NO: 27 of the Sequence Listing,regardless of whether it contains a leader peptide or not, is alsoincluded in the DNA of the present invention. (Note that, base sequencesare specified from amino acid sequences in accordance with the codes ofthe universal codons.) Namely, the present invention provides DNAs thatencode proteins indicated in (A) to (X) below:

(A) a protein having an amino acid sequence consisting of amino acidresidues numbers 23 to 616 of an amino acid sequence described in SEQ IDNO: 6 of the Sequence Listing,(B) a protein having an amino acid sequence including substitution,deletion, insertion, addition, and/or inversion of one or a plurality ofamino acids in amino acid residues numbers 23 to 616 of the amino acidsequence described in SEQ ID NO: 6 of the Sequence Listing, and havingpeptide-forming activity,(C) a protein having the amino acid sequence consisting of amino acidresidue numbers 21 to 619 of an amino acid sequence described in SEQ IDNO: 12 of the Sequence Listing,(D) a protein having an amino acid sequence including substitution,deletion, insertion, addition, and/or inversion of one or a plurality ofamino acids in amino acid residue numbers 21 to 619 of the amino acidsequence described in SEQ ID NO: 12 of the Sequence Listing, and havingpeptide-forming activity,(E) a protein having an amino acid sequence consisting of amino acidresidues numbers 23 to 625 of an amino acid sequence described in SEQ IDNO: 18 of the Sequence Listing,(F) a protein having an amino acid sequence including substitution,deletion, insertion, addition, and/or inversion of one or a plurality ofamino acids in amino acid residues numbers 23 to 625 of the amino acidsequence described in SEQ ID NO: 18 of the Sequence Listing, and havingpeptide-forming activity,(G) a protein having an amino acid sequence consisting of amino acidresidues numbers 23 to 645 of an amino acid sequence described in SEQ IDNO: 23 of the Sequence Listing,(H) a protein having an amino acid sequence including substitution,deletion, insertion, addition, and/or inversion of one or a plurality ofamino acids in amino acid residues numbers 23 to 645 of the amino acidsequence described in SEQ ID NO: 23 of the Sequence Listing, and havingpeptide-forming activity,(I) a protein having an amino acid sequence consisting of amino acidresidues numbers 26 to 620 of an amino acid sequence described in SEQ IDNO: 25 of the Sequence Listing,(J) a protein having an amino acid sequence including substitution,deletion, insertion, addition, and/or inversion of one or a plurality ofamino acids in amino acid residues numbers 26 to 620 of the amino acidsequence described in SEQ ID NO: 25 of the Sequence Listing, and havingpeptide-forming activity,(K) a protein having an amino acid sequence consisting of amino acidresidues numbers 18 to 644 of an amino acid sequence described in SEQ IDNO: 27 of the Sequence Listing,(L) a protein having an amino acid sequence including substitution,deletion, insertion, addition, and/or inversion of one or a plurality ofamino acids in amino acid residues numbers 18 to 644 of the amino acidsequence described in SEQ ID NO: 27 of the Sequence Listing, and havingpeptide-forming activity,(M) a protein having an amino acid sequence described in SEQ ID NO: 6 ofthe Sequence Listing,(N) a protein containing a mature protein region, having an amino acidsequence including substitution, deletion, insertion, addition, and/orinversion of one or a plurality of amino acids in the amino acidsequence described in SEQ ID NO: 6 of the Sequence Listing, and havingpeptide-forming activity,(O) a protein having the amino acid sequence described in SEQ ID NO: 12of the Sequence Listing,(P) a protein containing a mature protein region, having an amino acidsequence including substitution, deletion, insertion, addition, and/orinversion of one or a plurality of amino acids in an amino acid sequencedescribed in SEQ ID NO: 12 of the Sequence Listing, and havingpeptide-forming activity,(Q) a protein having an amino acid sequence described in SEQ ID NO: 18of the Sequence Listing,(R) a protein containing a mature protein region, having an amino acidsequence including substitution, deletion, insertion, addition, and/orinversion of one or a plurality of amino acids in the amino acidsequence described in SEQ ID NO: 18 of the Sequence Listing, and havingpeptide-forming activity,(S) a protein having an amino acid sequence described in SEQ ID NO: 23of the Sequence Listing,(T) a protein containing a mature protein region, having an amino acidsequence including substitution, deletion, insertion, addition, and/orinversion of one or a plurality of amino acids in the amino acidsequence described in SEQ ID NO: 23 of the Sequence Listing, and havingpeptide-forming activity,(U) a protein having an amino acid sequence described in SEQ ID NO: 25of the Sequence Listing,(V) a protein containing a mature protein region, having an amino acidsequence including substitution, deletion, insertion, addition, and/orinversion of one or a plurality of amino acids in the amino acidsequence described in SEQ ID NO: 25 of the Sequence Listing, and havingpeptide-forming activity;(W) a protein having an amino acid sequence described in SEQ ID NO: 27of the Sequence Listing, and(X) a protein containing a mature protein region, having an amino acidsequence in the amino acid sequence described in SEQ ID NO: 27 of theSequence Listing, and having peptide-forming activity.

Here, although the meaning of the term “a plurality of” varies dependingon the locations and types of the amino acid residues in thethree-dimensional structure of the protein, it is within a range thatdoes not significantly impair the three-dimensional structure andactivity of the protein of the amino acid residues, and is specifically2 to 50, preferably 2 to 30, and more preferably 2 to 10. However, inthe case of amino acid sequences including substitution, deletion,insertion, addition, and/or inversion of one or a plurality of aminoacids in amino acid sequences of the proteins of (B), (D), (F), (H),(J), (L), (N), (P), (R), (T), (V) or (X), it is preferable that theproteins retain about half or more, more preferably 80% or more, andeven more preferably 90% or more of the enzyme activity of the proteinsin the state where no mutation is included, under conditions of 50° C.and pH 8. For example, explanation will be made in the case of (B); inthe case of the amino acid sequence (B) including substitution,deletion, insertion, addition, and/or inversion of one or a plurality ofamino acids in the amino acid sequence described in SEQ ID NO: 6 of theSequence Listing, it is preferable that this protein retains about halfor more, more preferably 80% or more, and even more preferably 90% ormore of the enzyme activity of the protein having the amino acidsequence described in SEQ ID NO: 6 of the Sequence Listing, underconditions of 50° C. and pH 8.

A mutation of an amino acid like that indicated in the aforementioned(B) and so forth is obtained by modifying the base sequence so that anamino acid of a specific site in the present enzyme gene is substituted,deleted, inserted or added by, for example, site-directed mutagenesis.In addition, a modified DNA that described above can also be obtained bymutagenesis treatment known in the art. Mutagenesis treatment refers to,for example, a method in which a DNA encoding the present enzyme istreated in vitro with hydroxylamine and so forth, as well as a method inwhich bacteria belonging to the genus Escherichia that possess a DNAencoding the present enzyme are treated by a mutagen normally used inartificial mutagenesis, such as ultraviolet irradiation,N-methyl-N′-nitro-N-nitrosoguanidine (NTG) or nitrous acid.

In addition, naturally-occurring mutations such as differencesattributable to a microbe species or strain are also included in thebase substitution, deletion, insertion, addition and/or inversiondescribed above. By expressing a DNA having such a mutation in suitablecells and investigating the enzyme activity of the expression product, aDNA can be obtained that encodes a protein substantially identical tothe protein described in SEQ ID NO: 6 or 12 of the Sequence Listing.

(4-2) Preparation of Transformants and Production of Peptide-FormingEnzymes

Peptide-forming enzymes can be produced by introducing a DNA of thepresent invention into a suitable host and expressing the DNA in thathost.

Examples of hosts for expressing a protein specified by a DNA of thepresent invention that can be used include various prokaryotic cellssuch as bacteria belonging to the genus Escherichia such as Escherichiacoli, Empedobacter, Sphingobacterium, Flavobacterium and Bacillus suchas Bacillus subtilis, as well as various eukaryotic cells such asSaccharomyces cerevisiae, Pichia stipitis and Aspergillus oryzae.

A recombinant DNA used to introduce a DNA into a host can be prepared byinserting the DNA to be introduced into a vector corresponding to thetype of host in which the DNA is to be expressed, in such a form thatthe protein encoded by that DNA can be expressed. In the case where apromoter unique to a peptide-forming enzyme gene of Empedobacter brevisand so forth functions in the host cells, the promoter can be used as apromoter for expressing the DNA of the present invention. In addition,another promoter that acts on in the host cells may be ligated to theDNA of the present invention and the DNA may be expressed under thecontrol of the promoter as necessary.

Examples of transformation methods for introducing a recombinant DNAinto host cells include the method of D. M. Morrison (see Methods inEnzymology, 68, 326 (1979)) or the method in which DNA permeability isincreased by treating receptor microbial cells with calcium chloride(see Mandel, H. and Higa, A., J. Mol. Biol., 53, 159 (1970)).

In the case of mass production of a protein using recombinant DNAtechnology, conjugating the protein within a transformant that producesthe protein to form an inclusion body of protein is also a preferablemode for carrying out the present invention. Advantages of thisexpression and production method include protection of the targetprotein from digestion by proteases present in the microbial cells, andsimple and easy purification of the target protein by disrupting themicrobial cells, followed by centrifugation and so forth.

The inclusion bodies of protein obtained in this manner are solubilizedwith a protein denaturant and the solubilized protein is converted to aproperly folded, physiologically active protein by going through anactivity regeneration procedure that consists primarily of lysing theprotein with a protein denaturant followed by removal of the denaturant.There are numerous examples of this, including regeneration of theactivity of human interleukin-2 (see Japanese Patent ApplicationLaid-open Publication No. S61-257931).

To obtain an active protein from inclusion bodies of protein, a seriesof operations including solubilization and activity regeneration arerequired, and the procedure is more complex than in the case ofproducing the active protein directly. However, in the case of producinga large volume of protein that has a detrimental effect on microbialgrowth in microbial cells, that effect can be suppressed by accumulatingthe proteins in the form of inclusion bodies of inactive protein in themicrobial cells.

Examples of mass production methods for producing a large volume oftarget protein in the form of inclusion bodies include a method in whicha target protein is expressed independently under the control of apowerful promoter, and a method in which a target protein is expressedin the form of a fused protein with a protein that is known to beexpressed in a large volume.

Hereinafter, the present invention will be explained more specificallytaking as an example of a method for producing transformed Escherichiacoli and using the transformed microbe to produce a peptide-formingenzyme. Furthermore, in the case of producing a peptide-forming enzymein a microbe such as Escherichia coli, a DNA may be incorporated thatencodes a precursor protein containing a leader sequence or a DNA may beincorporated that consists only of a mature protein region that does notcontain a leader sequence, and the DNA can be suitably selected for theprotein encoding sequence depending on the production conditions, form,usage conditions and so forth of the enzyme to be produced.

Promoters normally used in the production of heterogeneous proteins inEscherichia coli can be used as promoters for expressing a DNA encodinga peptide-forming enzyme. Examples of such promoters include T7promoter, lac promoter, trp promoter, trc promoter, tac promoter, lambdaphage PR promoter, PL promoter and other powerful promoters. Inaddition, examples of vectors that can be used include pUC19, pUC18,pBR322, pHSG299, pHSG298, pHSG399, pHSG398, RSF1010, pMW119, pMW118,pMW219, and pMW218. Besides, vectors of phage DNA can also be used.Moreover, expression vectors can be used that contain promoters and arecapable of expressing an inserted DNA sequence, including the promotercan be used.

In order to produce a peptide-forming enzyme in the form of an inclusionbody of fused protein, a gene that encodes another protein, andpreferably a hydrophilic peptide is ligated upstream or downstream ofthe peptide-forming enzyme gene to obtain a fused protein gene. The genethat encodes another protein in this manner may be any gene thatincreases the amount of the fused protein accumulated, and enhances thesolubility of the fused protein after the denaturation and regenerationsteps. Examples of candidates for such genes include T7 gene 10,β-galactosidase gene, dehydrofolate reductase gene, γ-interferon gene,interleukin-2 gene and prochymosin gene.

When these genes are ligated to a gene that encodes a peptide-formingenzymes, the both genes are ligated so that their reading frames ofcodons are consistent. The genes may be ligated at a proper restrictionenzyme site or a synthetic DNA having a proper sequence may be utilized.

Further, to increase a production amount of the peptide-forming enzyme,it is preferable in some cases that a terminator, which is atranscription terminating sequence, be ligated to downstream of thefusion protein gene. The terminator includes, for example, a T7terminator, an fd phage terminator, a T4 terminator, a tetracyclineresistant gene terminator, and an Escherichia coli trpA gene terminator.

As the vectors for introducing a gene that encodes a peptide-formingenzyme or a fused protein between the peptide-forming enzyme and anotherprotein in Escherichia coli are preferred so-called multi-copy typevectors, examples of which include a plasmid having a replication originderived from ColE1, for example, a pUC-based plasmid, and a pBR322-basedplasmid or derivatives thereof. The “derivatives” as used herein referto those plasmids that are subjected to modification by substitution,deletion, insertion, addition and/or inversion of bases. Note that themodification as used herein includes modifications by a mutagenesistreatment with a mutagen or UV irradiation, or modifications byspontaneous mutation.

To screen transformants, it is preferable that the vectors have markerssuch as an ampicillin resistant gene. Such plasmids include commerciallyavailable expression vectors having potent promoters (a pUC-based vector(manufactured by Takara Shuzo, Co., Ltd.), pRROK-based vector(manufactured by Clonetech Laboratories, Inc.), pKK233-2 (manufacturedby Clonetech Laboratories, Inc.) and so forth.

A recombinant DNA is obtained by ligating a DNA fragment to a vectorDNA; in the DNA fragment, a promoter, a gene encoding L-amino acid amidehydrolase or a fused protein consisting of an L-amino acid amidehydrolase and another protein, and depending on the case, a terminatorare ligated in that order.

When E. coli is transformed using the recombinant DNA and the resultingE. coli is cultured, a peptide-forming enzyme or a fused proteinconsisting of the peptide-forming enzyme and another protein isexpressed and produced. Although a strain that is normally used in theexpression of a heterogeneous gene can be used as a host to betransformed, Escherichia coli strain JM109, for example, is preferable.Methods for carrying out transformation and methods for screening outtransformants are described in Molecular Cloning, 2nd Edition, ColdSpring Harbor Press (1989) and other publications.

In the case of expressing a peptide-forming enzyme in the form of afusion protein, the peptide-forming enzyme may be cleaved out using arestriction protease that uses a sequence not present in thepeptide-forming enzyme, such as blood coagulation factor Xa orkallikrein, as the recognition sequence.

A medium normally used for culturing E. coli, such as M9-casamino acidmedium or LB medium, may be used for as the a production medium. Inaddition, culturing conditions and production induction conditions aresuitably selected according to the marker of the vector used, promoter,type of host microbe and so forth.

The following method can be used to recover the peptide-forming enzymeor fused protein consisting of the peptide-forming enzyme and anotherprotein. If the peptide-forming enzyme or its fused protein has beensolubilized in the microbial cells, the microbial cells are recoveredand then disrupted or lysed so that they can be used as a crude enzymeliquid. Moreover, the peptide-forming enzyme or its fused protein can bepurified prior to use by ordinary techniques such as precipitation,filtration or column chromatography as necessary. In this case, apurification method can also be used that uses an antibody of thepeptide-forming enzyme or its fused protein.

In the case where inclusion bodies of protein are formed, the inclusionbodies are solubilized with a denaturant. Although they may besolubilized together with the microbial cell protein, it is preferablein consideration of the subsequent purification procedure that theinclusion bodies are taken out and then solubilized. Conventionallyknown methods may be used to recover the inclusion bodies from themicrobial cells. For example, the inclusion bodies can be recovered bydisrupting the microbial cells followed by centrifugation. Examples ofdenaturants capable of solubilizing the inclusion bodies includeguanidine hydrochloride (for example, 6 M, pH 5 to 8) and urea (forexample, 8 M) and the like.

A protein that has activity is regenerated by removing these denaturantsby dialysis or the like. A Tris-HCl buffer solution, a phosphate buffersolution or the like may be used as a dialysis solution to be used indialysis, and its concentration may be, for example, 20 mM to 0.5 M,while its pH may be, for example, 5 to 8.

The protein concentration during the regeneration step is preferablyheld to about 500 μg/ml or less. The dialysis temperature is preferably5° C. or lower to prevent the regenerated peptide-forming enzyme fromundergoing self-crosslinking. Moreover, the method for removing thedenaturants includes dilution or ultrafiltration in addition todialysis, and it is expected the activity can be regenerated whicheverdenaturant is used.

(5) Properties of Enzyme Encoded by DNA of the Present Invention

The activity of the enzyme encoded by the DNA of the present inventioncan be assayed by, for example, allowing the enzyme to react in a boratebuffer solution containing an amino acid ester and an amine assubstrates, and then quantifying the peptide formed. In a more concreteexample, the reaction is carried out at 25° C. for several minutes usinga borate buffer solution (pH 9.0) containing 100 mM L-alanine methylester and 200 mM L-glutamine.

The activity unit of the enzyme used in the present invention is definedsuch that 1 unit (U) is the amount of enzyme that produces 1 micromole(μmole) of peptide in 1 minute under the condition of reacting at 25° C.using a 100 mM borate buffer solution (pH 9.0) containing 100 mML-alanine methyl ester and 200 mM L-glutamine.

A protein encoded by the DNA of the present invention is apeptide-forming enzyme protein. Peptide-forming activity refers to theactivity that forms a peptide from a carboxy component and an aminecomponent. Hereinafter, a preferable mode of the enzyme encoded by theDNA of the present invention will be explained on its properties.

One preferable mode of the enzyme encoded by the DNA of the presentinvention includes an enzyme that has the abilities described below, forwhich the dipeptide production rate is used as an indicator. Namely, onepreferable mode of the enzyme of the present invention includes anenzyme that has the ability to form a peptide from a carboxy componentand an amino component, and has a production rate ofL-alanyl-L-glutamine in the dipeptide formation reaction under theconditions of (i) to (iv) below of preferably 0.03 mM/min or more, morepreferably 0.3 mM/min or more, and particularly preferably 1.0 mM/min ormore. The conditions of the dipeptide formation reaction are as follows:

(i) the carboxy component is L-alanine methyl ester hydrochloride (100mM);

(ii) the amine component is L-glutamine (200 mM);

(iii) the pH is 9.0; and,

(iv) the amount of homogenously purified enzyme added is less than 0.61mg/ml as a protein amount.

The aforementioned production rate far exceeds the conventionalproduction rate for peptide synthesis using an enzyme, and the enzyme ofthe present invention has the ability to catalyze peptide synthesis atan extremely rapid rate.

The aforementioned amount of enzyme added indicates a final amount ofthe enzyme that is added to the reaction system, and addition of theenzyme of 0.01 mg/ml or more, and preferably 0.02 mg/ml or more, asprotein amount is desirable. The term “protein amount” refers to thevalue indicated by a colorimetric method with Coomassie brilliant blueusing a protein assay CBB solution (manufactured by Nakarai) and bovineserum albumin as a standard substance.

In a specific example of the procedure for assaying the enzyme activity,the enzyme activity can be assayed by allowing the enzyme to react in aborate buffer solution containing an amino acid ester and an amine assubstrates and quantifying the resulting peptide. In a more specificexample, mention may be made of a method in which the enzyme is allowedto react for several minutes at 25° C. using a 100 mM borate buffersolution (pH 9.0) containing 100 mM L-alanine methyl ester and 200 mML-glutamine.

In addition, a preferable mode of the enzyme encoded by the DNA of thepresent invention includes an enzyme having the property by which bothan amino acid ester and an amino acid amide can be used as a substratefor the carboxy component. The words “both an amino acid ester and anamino acid amide can be used as a substrate” mean that at least one typeor more of amino acid ester and at least one type or more of amino acidamide can be used as a substrate. In addition, one preferable mode ofthe enzyme of the present invention includes an enzyme that has theproperty by which all of an amino acid, a C-protected amino acid and anamine can be used as a substrate for the amine component. The words “anamino acid, a C-protected amino acid, and an amine can be used as asubstrate” mean that at least one type or more of amino acid, at leastone type or more of C-protected amino acid, and at least one type ormore of amine can be used as a substrate. Having a wide range ofsubstrate specificity with respect to the carboxy component or the aminocomponent, the enzyme of the present invention is preferable in that awide range of raw materials can be selected, which in turn is favorablein terms of cost and production equipment in the case of industrialproduction.

Specific examples of the carboxy component include L-amino acid esters,D-amino acid esters, L-amino acid amides and D-amino acid amides. Inaddition, the amino acid esters include not only amino acid esterscorresponding to naturally-occurring amino acids, but also amino acidesters corresponding to non-naturally-occurring amino acids or theirderivatives. Furthermore, examples of the amino acid esters includeα-amino acid esters as well as β-, γ-, and ω-amino acid esters and thelike, which have different amino group bonding sites. Typical examplesof amino acid esters include methyl esters, ethyl esters, n-propylesters, iso-propyl esters, n-butyl esters, iso-butyl esters, andtert-butyl esters of amino acids.

Specific examples of the amine component include L-amino acids,C-protected L-amino acids, D-amino acids, C-protected D-amino acids andamines. In addition, examples of the amines include not onlynaturally-occurring amines, but also non-naturally-occurring amines ortheir derivatives. In addition, examples of the amino acids include notonly naturally-occurring amino acids, but also non-naturally-occurringamino acids or their derivatives. These include α-amino acids as well asβ-, γ- and ω-amino acids and the like, which have different amino groupbonding sites.

Further, in another aspect, one preferable mode of the enzyme encoded bythe DNA of the present invention includes an enzyme in which the pHrange over which the peptide-forming reaction can be catalyzed is 6.5 to10.5. The ability of the enzyme of the present invention to catalyzethis reaction over such a wide pH range as stated above is preferable inthat it allows flexible accommodation of industrial production thatcould be subject to the occurrence of various restrictions. However, inthe actual production of peptides, it is preferable to use the enzyme byfurther adjusting to an optimum pH corresponding to the obtained enzymeso as to maximize the catalytic performance of the enzyme.

Moreover, in another aspect, one preferable mode of the enzyme encodedby the DNA of the present invention includes an enzyme for which thetemperature range over which the enzyme is capable of catalyzing thepeptide-forming reaction is within the range of 0 to 60° C. Since theenzyme of the present invention is able to catalyze the reaction over awide temperature range, it is preferable in that it allows flexibleaccommodation of industrial production that could be subject to theoccurrence of various restrictions. However, in the actual production ofpeptides, it is preferable to use the enzyme by further adjusting to anoptimum temperature corresponding to the obtained enzyme so as tomaximize the catalytic performance of the enzyme.

(6) Dipeptide Production Method

The method for producing dipeptide of the present invention includesreaction between a carboxy component and an amine component in thepresence of the predetermined enzyme. The dipeptide production method ofthe present invention includes allowing an enzyme, or enzyme-containingsubstance, having the ability to form a peptide from a carboxy componentand an amine component, to act on the carboxy component and the aminecomponent to synthesize a dipeptide.

The method of allowing the enzyme or enzyme-containing substance used inthe present invention to act on the carboxy component and the aminecomponent may be mixing the enzyme or enzyme-containing substance, thecarboxy component, and the amine component with each other. Morespecifically, a method of adding the enzyme or enzyme-containingsubstance to a solution containing a carboxy component and an aminecomponent and allowing them to react may be used. Alternatively, in thecase of using a microbe that produces that enzyme, a method may be usedthat includes culturing the microbe that forms that enzyme, producingand accumulating the enzyme in the microbe or microbial culture broth,and then adding the carboxy component and amine component to the culturebroth. The produced dipeptide can then be collected by establishedmethods and purified as necessary.

The term “enzyme-containing substance” means any substance so far as itcontains the enzyme, and examples of specific forms thereof include aculture of microbes that produce the enzyme, microbial cells isolatedfrom the culture, and a product obtained by treating the microbial cells(hereinafter, “treated microbial cell product”). A culture of microbesrefers to what is obtained by culturing a microbe, and morespecifically, to a mixture of microbial cells, the medium used forculturing the microbe, and substances produced by the cultured microbe,and so forth. In addition, the microbial cells may be washed and used inthe form of washed microbial cells. In addition, the treated microbialcell product includes the products of disrupted, lysed or freeze-driedmicrobial cells, and the like, and also includes a crude enzymerecovered by treating microbial cells, and so forth, as well as apurified enzyme obtained by purification of the crude enzyme, and soforth. A partially purified enzyme obtained by various types ofpurification methods may be used for the purified enzyme, or immobilizedenzymes may be used that have been immobilized by a covalent bondingmethod, an adsorption method, an entrapment method, or the like. Inaddition, since some microbes are partially lysed during culturingdepending on the microbes used, the culture supernatant may also be usedas the enzyme-containing substance in such cases.

In addition, wild strains may be used as the microbes that contain theenzyme, or gene recombinant strains that express the enzyme may also beused. The microbes are not limited to intact microbial cells, but ratheracetone-treated microbial cells, freeze-dried microbial cells or othertreated microbial cells may also be used. Immobilized microbial cellsand an immobilized treated microbial cell product obtained byimmobilizing the microbial cells or treated microbial cell product bycovalent bonding, adsorption, entrapment or other methods, as well astreated immobilized microbial cells, may also be used.

Furthermore, when using cultures, cultured microbial cells, washedmicrobial cells or a treated microbial cell product that has beenobtained by disrupted or lysing microbial cells, it is often the casethat an enzyme exists therein that decomposes the formed peptideswithout being involved in peptide formation. In this situation, it maybe rather preferable in some cases to add a metal protease inhibitorlike ethylene diamine tetraacetic acid (EDTA). The addition amount iswithin the range of 0.1 millimolar (mM) to 300 mM, and preferably 1 mMto 100 mM.

A preferable mode of the dipeptide production method of the presentinvention is a method in which the transformed cells described in thepreviously described section (4-2) are cultured in a medium, and apeptide-forming enzyme is allowed to accumulate in the medium and/ortransformed cells. Since the peptide-forming enzyme can be easilyproduced in large volumes by using a transformant, dipeptides can beproduced in large amounts and rapidly.

The amount of enzyme or enzyme-containing substance used may be enoughif it is an amount at which the target effect is demonstrated (effectiveamount), and this effective amount can be easily determined throughsimple, preliminary experimentation by a person with ordinary skill inthe art. In the case of using the enzyme, for example, the amount usedis about 0.01 U to about 100 U, while in the case of using washedmicrobial cells, the amount used is about 1 g/L to about 500 g/L.

Any carboxy component may be used as far as it can form a peptide bycondensation with the other substrate in the form of the aminecomponent. Examples of carboxy component include L-amino acid esters,D-amino acid esters, L-amino acid amides and D-amino acid amides as wellas organic acid esters not having an amino group. In addition, examplesof amino acid esters include not only amino acid esters corresponding tonaturally-occurring amino acids, but also amino acid esterscorresponding to non-naturally-occurring amino acids or theirderivatives. In addition, examples of amino acid esters include α-aminoacid esters as well as β-, γ- and ω-amino acid esters and the likehaving different amino group bonding sites. Typical examples of aminoacid esters include methyl esters, ethyl esters, n-propyl esters,iso-propyl esters, n-butyl esters, iso-butyl esters and tert-butylesters of amino acids.

Any amine component may be used as far as it can form a peptide bycondensation with the other substrate in the form of the carboxycomponent. Examples of the amine component include L-amino acids,C-protected L-amino acids, D-amino acids, C-protected D-amino acids andamines. In addition, examples of the amines include not onlynaturally-occurring amines, but also non-naturally-occurring amines ortheir derivatives. In addition, examples of the amino acids include notonly naturally-occurring amino acids, but also non-naturally-occurringamino acids or their derivatives. These include α-amino acids as well asβ-, γ- or ω-amino acids and the like having different amino groupbonding sites.

The concentrations of the carboxy component and amine component servingas starting materials are 1 mM to 10 M, and preferably 0.05 M to 2 M,respectively; however, there are cases where it is preferable to addamine component in an amount equimolar or excess molar with respect tothe carboxy component. In addition, in cases where high concentrationsof substrates inhibit the reaction, these can be added stepwise duringthe reaction after they are adjusted to concentrations that do not causeinhibition.

The reaction temperature that allows synthesis of peptide is 0 to 60°C., and preferably 5 to 40° C. In addition, the reaction pH that allowssynthesis of peptide is 6.5 to 10.5, and preferably 7.0 to 10.0.

EXAMPLES

Hereinafter, the present invention will be explained by examples.However, the present invention is not limited to these examples. Inaddition to confirmation by ninhydrin coloring of thin-filmchromatograms (qualitative), quantitative determinations were made bythe following high-performance liquid chromatography in order to assayproducts. Column: InertsiL ODS-2 (manufactured by GL Science, Inc.),eluate: an aqueous phosphate solution containing 5.0 mM sodium1-octanesulfonate (pH 2.1):methanol=100:15 to 50, flow rate: 1.0 mL/min,detection: 210 nanometers (hereinafter, “nm”).

Example 1 Microbe Culturing (Empedobacter brevis Strain FERM BP-8113)

A 50 mL medium (pH 6.2) containing 5 grams (g) of glucose, 5 g ofammonium sulfate, 1 g of monopotassium phosphate, 3 g of dipotassiumphosphate, 0.5 g of magnesium sulfate, 10 g of yeast extract and 10 g ofpeptone in 1 liter (L) was transferred to a 500 mL Sakaguchi flask andsterilized at 115° C. for 15 minutes. This medium was then inoculatedwith one loopful cells of Empedobacter brevis strain FERM BP-8113(Depositary institution: the independent administrative corporation,National Institute of Advanced Industrial Science and Technology,International Patent Organism Depositary, Address of depositaryinstitution: Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken,Japan, International deposit transfer date: Jul. 8, 2002) that had beencultured at 30° C. for 16 hours in the same medium, followed by shakeculturing at 30° C. for 16 hours and 120 strokes/min.

Example 2 Production of Peptide Using Microbial Cells

Microbial cells were collected by centrifuging (10,000 rounds per minute(rpm), 15 minutes) the culture broth obtained in Example 1, followed bysuspending them to a concentration of 100 g/L in 100 mM borate buffer(pH 9.0) containing 10 mM EDTA. After respectively adding 1 mL of thesuspension to 1 mL each of 100 mM borate buffer solutions (pH 9.0)containing 10 mM EDTA, 200 mM of the following carboxy components, and400 mM of the following amino acids to make a final volume of 2 mL, thereaction was carried out at 18° C. for 2 hours. The peptides that wereformed as a result of this reaction are shown in Table 1.

TABLE 1 Carboxy Amine Formed component component peptide (mM) L-Ala-OMeL-Leu L-Ala-L-Leu 38.2 L-Met L-Ala-L-Met 68.3 L-Phe L-Ala-L-Phe 62.4L-Ser L-Ala-L-Ser 51.3 L-His L-Ala-L-His 52.1 L-Arg L-Ala-L-Arg 72.1L-Gln L-Ala-L-Gln 68.0 Gly-OMe L-His L-Gly-L-His 22.1 L-Ser-OMe L-SerL-Ser-L-Ser 29.0 L-Val-OMe L-Met L-Val-L-Met 10.5 L-Met-OMe L-PheL-Met-L-Phe 28.5 L-Thr-OMe L-Leu L-Thr-L-Leu 23.0 L-Ile-OMe L-MetL-Ile-L-Met 8.3 Hydrochloride salts were used for all the carboxycomponents.

Example 3 Purification of Enzyme

The procedure after centrifugation was carried out either on ice or at4° C. Empedobacter brevis strain FERM BP-8113 (Depositary institution:the independent administrative corporation, National Institute ofAdvanced Industrial Science and Technology, International PatentOrganism Depositary, Address of depositary institution: Chuo Dai-6, 1-1Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, International deposittransfer date: Jul. 8, 2002) was cultured in the same manner in asExample 1, and the microbial cells were collected by centrifugation(10,000 rpm, 15 minutes). After washing 16 g of microbial cells with 50mM Tris-HCl buffer (pH 8.0), they were suspended in 40 milliliters (mlor mL) of the same buffer and subjected to ultrasonic disruptingtreatment for 45 minutes at 195 watts. This ultrasonically disruptedliquid was then centrifuged (10,000 rpm, 30 minutes) to remove the celldebris and obtain an ultrasonically disrupted liquid supernatant. Thisultrasonically disrupted liquid supernatant was dialyzed overnightagainst 50 mM Tris-HCl buffer (pH 8.0) followed by removal of theinsoluble fraction by ultracentrifugation (50,000 rpm, 30 minutes) toobtain a soluble fraction in the form of the supernatant liquid. Theresulting soluble fraction was applied to a Q-Sepharose HP column(manufactured by Amersham) pre-equilibrated with Tris-HCl buffer (pH8.0), and the active fraction was collected from the non-adsorbedfraction. This active fraction was dialyzed overnight against 50 mMacetate buffer (pH 4.5) followed by removal of the insoluble fraction bycentrifugation (10,000 rpm, 30 minutes) to obtain a dialyzed fraction inthe form of the supernatant liquid. This dialyzed fraction was thenapplied to a Mono S column (manufactured by Amersham) pre-equilibratedwith 50 mM acetate buffer (pH 4.5) to elute enzyme at a linearconcentration gradient of the same buffer containing 0 to 1 M NaCl. Thefraction that had the lowest level of contaminating protein among theactive fractions was applied to a Superdex 200pg column (manufactured byAmersham) pre-equilibrated with 50 mM acetate buffer (pH 4.5) containing1 M NaCl, and gel filtration was performed by allowing the same buffer(pH 4.5) containing 1 M NaCl to flow through the column to obtain anactive fraction solution. As a result of performing these operations,the peptide-forming enzyme used in the present invention was confirmedto have been uniformly purified based on the experimental results ofelectrophoresis. The enzyme recovery rate in the aforementionedpurification process was 12.2% and the degree of purification was 707folds.

Example 4 Measurement of Molecular Weight of Enzyme

SDS-Gel Electrophoresis

A 0.3 microgram (μg) equivalent of the purified enzyme fraction obtainedby the method of Example 3 was applied to polyacrylamideelectrophoresis. 0.3% (w/v) Tris, 1.44% (w/v) glycine and 0.1% (w/v)sodium laurylsulfate were used for the electrophoresis buffer solution,a gel having a concentration gradient of a gel concentration of 10 to20% (Multigel 10 to 20, manufactured by Daiichi Pure Chemicals) was usedfor the polyacrylamide gel, and Pharmacia molecular weight markers wereused as the molecular weight markers. Following completion ofelectrophoresis, the gel was stained with Coomassie brilliant blueR-250, and a uniform band was detected at the location of a molecularweight of about 75 kilodaltons (kDa).

Gel Filtration

The purified enzyme fraction obtained by the method of Example 3 wasapplied to a Superdex 200pg column (manufactured by Amersham)pre-equilibrated with 50 mM acetate buffer (pH 4.5) containing 1 M NaCl,and gel filtration was carried out by allowing the same buffer (pH 4.5)containing 1 M NaCl to flow through the column to measure the molecularweight. Pharmacia molecular weight markers were used as standardproteins having known molecular weights to prepare a calibration curve.As a result, the molecular weight of the enzyme was about 150 kDa.

Based on the results of SDS-gel electrophoresis and gel filtration, theenzyme was suggested to be a homodimer having a molecular weight ofabout 75 kDa.

Example 5 Optimum pH for Enzyme Reaction

The effects of pH were examined in the reaction in whichL-alanyl-L-glutamine is formed from L-alanine methyl ester hydrochlorideand L-glutamine. Acetate buffer (pH 3.9 to 5.4), MES buffer (pH 5.4 to6.4), phosphate buffer (pH 6.0 to 7.9), borate buffer (pH 7.8 to 9.3),CAPS buffer (pH 9.3 to 10.7), and K₂HPO₄—NaOH buffer (pH 10.8 to 11.6)were used as buffers. 1 microliter (μl) of the Mono S fraction enzymeobtained in Example 3 (about 180 U/ml) was added to 100 μl of eachbuffer (100 mM) containing 100 mM L-alanine methyl ester, 200 mML-glutamine and 10 mM EDTA and allowed to react at 18° C. for 5 minutesto measure the effects of pH on the reaction. The results expressed byassigning a value of 100% to the case of using borate buffer (pH 9.3)are shown in FIG. 1. As a result, the optimum pH was found to be 8 to9.5.

Example 6 Optimum Temperature for Enzyme Reaction

The effects of temperature were examined on the reaction in whichL-alanyl-L-glutamine is formed from L-alanine methyl ester hydrochlorideand L-glutamine. 1 μl of the same enzyme fraction used in Example 5 wasadded to 100 μl of 100 mM borate buffer (pH 9.0) containing 100 mML-alanine methyl ester, 200 mM L-glutamine and 10 mM EDTA and allowed toreact for 5 minutes at each temperature to measure the effects oftemperature on the reaction. The results based on assigning a value of100% to the activity at 34° C. are shown in FIG. 2. As a result, theoptimum temperature was 30 to 40° C.

Example 7 Enzyme Inhibitors

The effects of inhibitors on the production of L-alanyl-L-glutamine wereexamined using L-alanine methyl ester hydrochloride and L-glutamine assubstrates. 2 μl of the same enzyme fraction used in Example 5 was addedto 50 μl of 100 mM borate buffer (pH 9.0) containing each of the enzymeinhibitors shown in Table 2 at 10 mM, and allowed to react at 25° C. for5 minutes. Note that, o-phenanthroline, phenylmethylsulfonyl fluorideand p-nitrophenyl-p′-guanidinobenzoate were dissolved in methanol to aconcentration of 50 mM before use. The enzyme activity under eachcondition was indicated as the relative activity in the case ofassigning a value of 100 to the production of L-alanyl-L-glutamine inthe absence of enzyme inhibitor. Those results are shown in Table 2. Asa result, among the serine enzyme inhibitors tested, the enzyme was notinhibited by phenylmethylsulfonyl fluoride, but it was inhibited byp-nitrophenyl-p′-guanidinobenzoate.

TABLE 2 Relative activity of L-Ala-L-Gln production Enzyme inhibitor (%)None 100 Metal enzyme EDTA 96 inhibitor o-Phenanthroline 96 SH enzymeN-Ethyl maleimide 110 inhibitor Monoiodoacetate 101 Serine enzymePhenylmethylsulfonyl 115 inhibitor fluoride 4-(2-Aminoethyl)benzene 75sulfonyl fluoride p-Nitrophenyl-p′-guanidino 0.1 benzoate

Example 8 Production of L-Alanyl-L-Glutamine from L-Alanine Methyl Esterand L-Glutamine

3 μl of the same enzyme fraction as used in Example 5 was added to 100μl of 100 mM borate buffer (pH 9.0) containing 100 mM L-alanine methylester hydrochloride, 200 mM L-glutamine and 10 mM EDTA, and allowed toreact at 18° C. As a result, as shown in FIG. 3, 83 mML-alanyl-L-glutamine (L-Ala-L-Gln) was formed in the case of anenzyme-added lot, and the concentration of by-product L-Ala-L-Ala-L-Glnwas 1.3 mM. On the other hand, there was scarcely any production ofL-Ala-L-Gln observed in an enzyme-non-added lot, and the enzymeconcentration was only about 0.07 mM after reacting for 120 minutes.

Example 9 Effects of L-Glutamine Concentration on Production ofL-Alanyl-L-Glutamine

1 μl of the same enzyme fraction as used in Example 5 was added to 100μl of 100 mM borate buffer (pH 9.0) containing 100 mM L-alanine methylester hydrochloride, L-glutamine at the concentrations shown in Table 3and 10 mM EDTA, and allowed to react at 18° C. for 2 hours. Thoseresults are shown in Table 3.

TABLE 3 L-Alanine methyl ester L-Glutamine L-Ala-L-Gln hydrochloride(mM) (mM) (mM) 100 100 68.2 110 72.1 120 73.3 130 75.1 150 75.5 200 82.0

Example 10 Substrate Specificity of Enzyme (1)

Ester specificity was examined in the case of using L-amino acid esterfor the carboxy component. 2 μl of the same enzyme fraction as used inExample 5 was added to 100 μl of 100 mM borate buffer (pH 9.0)containing the carboxy components indicated in Table 4 at 100 mM, 200 mML-glutamine and 10 mM EDTA, and allowed to react at 25° C. for 2 hours.The amounts of L-Ala-L-Gln formed in this reaction are shown in Table 4.HCl represents hydrochloride in Table 4.

TABLE 4 Carboxy component L-Ala-L-Gln formed (mM) L-Alanine methylester•HCl 84.3 L-Alanine ethyl ester•HCl 91.5 L-Alanine isopropylester•HCl 78.9 L-Alanine-t-butyl ester•HCl 7.5

Example 11 Substrate Specificity of Enzyme (2)

Peptide production was examined in the case of using L-alanine methylester for the carboxy component and using various L-amino acids for theamine component. 2 μl of the same enzyme fraction as used in Example 5was added to 100 μl of 100 mM borate buffer (pH 9.0) containing 100 mML-alanine methyl ester hydrochloride, the L-amino acids shown in Table 5at 150 mM and 10 mM EDTA, and allowed to react at 25° C. for 3 hours.The amounts of various peptides formed in this reaction are shown inTable 5. The “+” mark indicates those peptides for which production wasconfirmed but which were unable to be quantified due to the absence of astandard, while “tr” indicates a trace amount.

TABLE 5 Amine component Formed peptide (mM) Gly L-Ala-Gly 13.7 L-AlaL-Ala-L-Ala 25.4 L-Val L-Ala-L-Val 20.8 L-Leu L-Ala-L-Leu 45.3 L-IleL-Ala-L-Ile 33.9 L-Met L-Ala-L-Met 83.3 L-Phe L-Ala-L-Phe 74.4 L-TrpL-Ala-L-Trp 53.9 L-Ser L-Ala-L-Ser 62.5 L-Thr L-Ala-L-Thr 53.9 L-AsnL-Ala-L-Asn 65.5 L-Gln L-Ala-L-Gln 79.3 L-Tyr L-Ala-L-Tyr 17.6 L-CySHL-Ala-L-CySH + L-Lys L-Ala-L-Lys 71.8 L-Arg L-Ala-L-Arg 88.0 L-HisL-Ala-L-His 66.9 L-Asp L-Ala-L-Asp  2.1 L-Glu L-Ala-L-Glu 42.9 L-ProL-Ala-L-Pro tr

Example 12 Substrate Specificity of Enzyme (3)

Peptide production was examined in the case of using various types ofL-amino acid methyl esters for the carboxy component and usingL-glutamine for the amine component. 2 μl of the same enzyme fraction asused in Example 5 was added to 100 μl of 100 mM borate buffer (pH 9.0)containing the L-amino acid methyl ester hydrochloride salts(AA-OMe.HCl) shown in Table 6 at 100 mM, 150 mM L-glutamine and 10 mMEDTA, and allowed to react at 25° C. for 3 hours. The amounts of variouspeptides formed in this reaction are shown in Table 6. The “+” markindicates those peptides for which production was confirmed but whichwere unable to be quantified due to the absence of a standard, while“tr” indicates a trace amount. Furthermore, Tween-80 was added to thereaction system to a final concentration of 0.1% in the case of usingL-Trp-OMe and L-Tyr-OMe.

TABLE 6 Carboxy component Formed peptide (mM) Gly-OMe Gly-L-Gln 54.7L-Ala-OMe L-Ala-L-Gln 74.6 L-Val-OMe L-Val-L-Gln 15.4 L-Leu-OMeL-Leu-L-Gln + L-Ile-OMe L-Ile-L-Gln  8.4 L-Met-OMe L-Met-L-Gln 12.0L-Phe-OMe L-Phe-L-Gln  0.9 L-Trp-OMe L-Trp-L-Gln + L-Ser-OMe L-Ser-L-Gln24.0 L-Thr-OMe L-Thr-L-Gln 81.9 L-Asn-OMe L-Asn-L-Gln + L-Gln-OMeL-Gln-L-Gln  0.3 L-Tyr-OMe L-Tyr-L-Gln  3.4 CySH-OMe L-CySH-L-Gln +L-Lys-OMe L-Lys-L-Gln + L-Arg-OMe L-Arg-L-Gln  7.1 L-His-OMeL-His-L-Gln + L-Asp-α-OMe α-L-Asp-L-Gln tr L-Asp-β-OMe β-L-Asp-L-Gln trL-Glu-α-OMe α-L-Glu-L-Gln + L-Glu-γ-OMe γ-L-Glu-L-Gln + L-Pro-OMeL-Pro-L-Gln  2.2 Hydrochloride salts were used for all the carboxycomponents.

Example 13 Substrate Specificity of Enzyme (4)

Peptide production was examined in the case of using various L-aminoacid methyl esters for the carboxy component and various L-amino acidsfor the amine component. 2 μl of the same enzyme fraction as used inExample 5 was added to 100 μl of 100 mM borate buffer (pH 9.0)containing the L-amino acid methyl ester hydrochloride salts(AA-OMe.HCl) shown in Table 7 at 100 mM, the L-amino acids shown inTable 7 at 150 mM and 10 mM EDTA, and allowed to react at 25° C. for 3hours. The amounts formed of each of the peptides formed in thisreaction are shown in Table 7. The “tr” indicates a trace amount.Furthermore, Tween-80 was added to the reaction system to a finalconcentration of 0.1% in the case of using L-Trp-OMe. The “+” markindicates those peptides for which production was confirmed but whichwere unable to be quantified due to the absence of a standard.

TABLE 7 Carboxy Amine Formed component component peptide (mM) Gly-OMeL-CySH Gly-L-CySH 45.6 L-Arg Gly-L-Arg 25.5 L-Phe Gly-L-Phe 44.0 L-HisGly-L-His 31.6 L-Lys Gly-L-Lys 9.8 L-Ser Gly-L-Ser 44.2 L-Thr-OMe GlyL-Thr-Gly 9.4 L-Ala L-Thr-L-Ala 9.4 L-Val L-Thr-L-Val 0.7 L-LeuL-Thr-L-Leu 28.4 L-Met L-Thr-L-Met 38.6 L-Ser L-Thr-L-Ser 58.2 L-Ser-OMeL-Ser L-Ser-L-Ser 38.0 L-Met L-Ser-L-Met 12.5 L-Phe L-Ser-L-Phe 20.3L-Val-OMe L-Ser L-Val-L-Ser 30.8 L-Met L-Val-L-Met 10.3 L-PheL-Val-L-Phe 6.1 L-Met-OMe L-Ser L-Met-L-Ser 12.8 L-Met L-Met-L-Met 25.0L-Phe L-Met-L-Phe 34.0 L-Ile-OMe L-Ser L-Ile-L-Ser 17.2 L-MetL-Ile-L-Met 10.0 L-Phe L-Ile-L-Phe 5.2 L-Arg-OMe L-Ser L-Arg-L-Ser 3.6L-Met L-Arg-L-Met 0.7 L-Phe L-Arg-L-Phe 1.9 L-Leu-OMe L-Met L-Leu-L-Met12.2 L-Trp-OMe L-Met L-Trp-L-Met 4.1 L-Lys-OMe L-Met L-Lys-L-Met 6.8L-His-OMe L-Met L-His-L-Met 6.5 L-Asn-OMe L-Glu L-Asn-L-Glu 10.2Hydrochloride salts were used for all the carboxy components.

Example 14 Substrate Specificity of Enzyme (5)

Peptide production was examined in the case of using the L or D forms ofvarious amino acid methyl esters for the carboxy component, and the L orD forms of various amino acids for the amine component. 2 μl of the sameenzyme fraction as used in Example 5 was added to 100 μl of 100 mMborate buffer (pH 9.0) containing the various amino acid methyl esterhydrochloride salts (AA-OMe.HCl) shown in Table 8 at 100 mM, the variousamino acids shown in Table 8 at 150 mM and 10 mM EDTA, and allowed toreact at 25° C. for 3 hours. The amounts of various peptides formed inthis reaction are shown in Table 8. The “tr” indicates a trace amount.

TABLE 8 Carboxy Amine Formed component component peptide (mM) D-Ala-OMeL-Gln D-Ala-L-Gln 69.3 D-Ala-OMe L-Ser D-Ala-L-Ser 20.3 D-Thr-OMeD-Thr-L-Ser 1.0 D-Ser-OMe D-Ser-L-Ser 3.3 D-Val-OMe D-Val-L-Ser 0.6D-Met-OMe D-Met-L-Ser 5.1 L-Ala-OMe D-Gln L-Ala-D-Gln 0.3 L-Ala-OMeD-Ser L-Ala-D-Ser 5.4 L-Thr-OMe L-Thr-D-Ser 6.9 L-Ser-OMe L-Ser-D-Ser16.2 L-Val-OMe L-Val-D-Ser 1.4 L-Met-OMe L-Met-D-Ser 1.9 D-Ala-OMe D-GlnD-Ala-D-Gln tr D-Ala-OMe D-Ser D-Ala-D-Ser 0.2 D-Thr-OMe D-Thr-D-Ser 1.1D-Ser-OMe D-Ser-D-Ser 2.5 D-Val-OMe D-Val-D-Ser 0.5 D-Met-OMeD-Met-D-Ser 2.7 Hydrochloride salts were used for all the carboxycomponents.

Example 15 Substrate Specificity of Enzyme (6)

Peptide production was examined using various L-amino acid amides forthe carboxy component, and various L-amino acids for the aminecomponent. 2 μl of the same enzyme fraction as that used in Example 5was added to 100 μl of 100 mM borate buffer (pH 9.0) containing theL-amino acid amide hydrochloride salts (AA-NH₂.HCl) shown in Table 9 at100 mM, the L-amino acids shown in Table 9 at 150 mM and 10 mM EDTA, andallowed to react at 25° C. for 3 hours. The amounts of various peptidesformed in this reaction are shown in Table 9.

TABLE 9 Carboxy Amine Formed component component peptide (mM) L-Phe-NH₂L-Gln L-Phe-L-Gln 0.2 L-Phe-NH₂ L-Ser L-Phe-L-Ser 0.6 L-Ala-NH₂ L-GlnL-Ala-L-Gln 7.6 L-Ala-NH₂ L-Met L-Ala-L-Met 3.4 L-Ala-NH₂ L-HisL-Ala-L-His 3.9 L-Thr-NH₂ L-Gln L-Thr-L-Gln 0.3

Example 16 Substrate Specificity of Enzyme (7)

Peptide production was examined in the case of using various L-alaninemethyl esters for the carboxy component and C-protected L-amino acidsfor the amine component. 2 μl of the same enzyme fraction as used inExample 5 was added to 100 μl of 100 mM borate buffer (pH 9.0)containing the L-alanine methyl ester hydrochloride salt (Ala-OMe.HCl)shown in Table 10 at 100 mM, the L-amino acid amide hydrochloride saltsshown in Table 10 at 150 mM and 10 mM EDTA, and allowed to react at 25°C. for 3 hours. The amounts of various peptides formed in this reactionare shown in Table 10.

TABLE 10 Carboxy Amine Formed component component peptide (mM) L-Ala-OMeGly-NH₂ L-Ala-Gly-NH₂ 7.4 L-Ala-NH₂ L-Ala-L-Ala-NH₂ 8.3 L-Phe-NH₂L-Ala-L-Phe-NH₂ 12.2

Example 17 Substrate Specificity of Enzyme (8)

Peptide production was examined in the case of using various amino acidmethyl esters for the carboxy component and methylamine for the aminecomponent. 2 μl of the same enzyme fraction as used in Example 5 wasadded to 100 μl of 100 mM borate buffer (pH 9.0) containing the aminoacid methyl ester hydrochloride salts (AA-OMe.HCl) shown in Table 11 at100 mM, the methylamine shown in Table 11 at 150 mM and 10 mM EDTA, andallowed to react at 25° C. for 3 hours. The amounts of various peptidesformed in this reaction are shown in Table 11.

TABLE 11 Carboxy Amine Formed component component peptide (mM) Gly-OMeMethylamine Gly-methylamine 1.1 L-Thr-OMe L-Thr-methylamine 0.2L-Ala-OMe L-Ala-methylamine 0.3

Example 18 Substrate Specificity of Enzyme (9)

Peptide production was examined in the case of using n-amino acid esterfor the carboxy component or β-amino acid for the amine component. 2 μlof the same enzyme fraction as used in Example 5 was added to 100 μl of100 mM borate buffer (pH 9.0) containing the carboxy components shown inTable 12 at 100 mM, the amine components shown in Table 12 at 150 mM and10 mM EDTA, and allowed to react at 25° C. for 3 hours. The amounts ofvarious peptides formed in this reaction are shown in Table 12. The “tr”indicates a trace amount.

TABLE 12 Carboxy Amine Formed component component peptide (mM) Gly-OMeβ-Ala Gly-β-Ala 2.2 Gly-OMe β-Phe Gly-β-Phe 0.4 L-Ala-OMe β-AlaAla-β-Ala 7.7 L-Ala-OMe β-Phe Ala-β-Phe 1.4 L-Thr-OMe β-Ala Thr-β-Ala3.2 L-Thr-OMe β-Phe Thr-β-Phe 1.4 β-Ala-OMe L-α-Ala β-Ala-L-α-Ala trβ-Ala-OMe β-Ala β-Ala-β-Ala 0.2 β-Ala-OMe L-Gln β-Ala-L-Gln 0.6β-Ala-OMe L-Ser β-Ala-L-Ser 3.2 Hydrochloride salts were used for all ofthe carboxy components.

Example 19 Substrate Specificity of Enzyme (10)

Oligopeptide production was examined in the case of using L-amino acidester for the carboxy component and peptide for the amine component. 2μl of the same enzyme fraction as used in Example 5 was added to 100 μlof 100 mM borate buffer (pH 9.0) containing the carboxy components shownin Table 13 at 100 mM, the amine components shown in Table 13 at 150 mMand 10 mM EDTA, and allowed to react at 25° C. for 3 hours. The amountsof various peptides formed in this reaction are shown in Table 13. As aresult, it was clearly demonstrated that the present enzyme can form notonly dipeptide, but also long-chain peptides by using a peptide for theamine component.

As has been indicated in the aforementioned Examples 9 to 20, thepresent enzyme obtained from Empedobacter brevis strain FERM BP-18545was determined to have extremely broad substrate specificity.

TABLE 13 Carboxy Amine Produced component component peptide (mM)L-Ala-OMe L-Ala L-Ala-L-Ala 28.7 L-Ala-L-Ala L-Ala-L-Ala-L-Ala 57.5L-Ala-L-Ala-L-Ala L-Ala-L-Ala-L-Ala- 44.5 L-Ala L-Ala-L-Ala-L-Ala-L-Ala-L-Ala-L-Ala- 34.8 L-Ala L-Ala-L-Ala L-Ala-L-Ala-L-Ala-L-Ala-L-Ala-L-Ala- 1.4* L-Ala-L-Ala L-Ala-L-Ala-L-Ala L-Ala-L-GlnL-Ala-L-Ala-L-Gln 15.2 Gly-L-Ala L-Ala-Gly-L-Ala 25.9 Gly-GlyL-Ala-Gly-Gly 41.7 L-His-L-Ala L-Ala-L-His-L-Ala 55.9 L-Leu-L-AlaL-Ala-L-Leu-L-Ala 48.3 L-Phe-L-Ala L-Ala-L-Phe-L-Ala 49.7 L-Phe-GlyL-Ala-L-Phe-Gly 43.7 Gly-OMe L-Ala-L-Tyr Gly-L-Ala-L-Tyr 1.7 Gly-L-GlnGly-Gly-L-Gln 7.2 Gly-L-Tyr-L-Ala Gly-Gly-L-Tyr-L-Ala 44.2 L-Thr-OMeGly-Gly L-Thr-Gly-Gly 83.0 *Since the solubility ofL-Ala-L-Ala-L-Ala-L-Ala-L-Ala was low, the carboxy component was used ata concentration of 10 mM and the amine component was used at 15 mM inthis reaction system. The other conditions were the same as thoseexplained in the example. Hydrochloride salts were used for all thecarboxy components.

Example 20 Comparison of Ability to Catalyze Peptide Formation withKnown Enzymes

The peptide-forming ability of the present enzyme was compared with thatof known enzymes. Carboxypeptidase Y described in EP 278787A1 and thethiol endopeptidases (ficin, papain, bromelain, and chymopapain)described in EP 359399B1 were used as the known enzymes, and they wereused in the form of purified enzymes (manufactured by Sigma). The enzymeuniformly purified in Example 3 was used as a source of the presentenzyme of the present invention. These enzymes were added to a reactionsystem in the protein amounts shown in Table 14. The reaction wascarried out by adding the enzyme to 100 μl of borate buffer (pH 9.0)containing 100 mM L-alanine methyl ester hydrochloride and 200 mML-glutamine and allowing the resultant to react at 25° C. Note that thecarboxypeptidase used was one dissolved in 10 mM acetate buffer (pH 5.0)containing 1 mM EDTA, while the thiol endopeptidase used was onedissolved in 10 mM acetate buffer (pH 5.0) containing 2 mM EDTA, 0.1 MKCl, and 5 mM dithiothreitol. The ratios of the production rates ofL-alanyl-L-glutamine by these enzymes are shown in Table 14.

As a result, the production of an extremely trace small amount ofL-alanyl-L-glutamine was observed even in the absence of enzymes, whilea slight increase in the production rate was observed in the sectionwhere carboxypeptidase- or thiol endopeptidase-added lot as comparedwith the enzyme-non-added lot. In contrast, an overwhelmingly higherrate of production of L-alanyl-L-glutamine was observed in theenzyme-added lot, and that rate of production was about 5,000 to 100,000times higher than those of carboxypeptidase Y and of thiolendopeptidase. As has been described above, the present enzyme wasverified to have an extremely high peptide production rate unlike anyknown enzyme in the prior art. Furthermore, the enzyme of the presentinvention is a dimer having a molecular weight of about 75,000. Incontrast, the molecular weight of the carboxypeptidase Y has beenreported to be about 61,000, while the molecular weight of thiolendopeptidase has been reported to be about 23,000 to 36,000. Thus, theL-alanyl-L-glutamine production rate of the enzyme of the presentinvention as compared to those of the carboxypeptidase Y and the thiolendopeptidase is even greater when the rate is expressed per molecularweight than when it is expressed per unit weight as indicated in theexamples.

TABLE 14 Ratio of L-Ala-L-Gln L-Ala-L-Gln Amount of productionproduction rate enzyme added rate per enzyme Enzyme (protein mg/ml)(mM/min) unit weight No enzyme 0 0.0006 Carboxypeptidase Y 0.61 0.02570.0191 Ficin 2.60 0.0096 0.0017 Papain 2.30 0.0106 0.0021 Bromelain 2.800.0062 0.0010 Chymopapain 3.60 0.0100 0.0013 Enzyme of present 0.024.4000 100.0 invention

Example 21 Production of L-Alanyl-L-Glutamine Using Microbial Cell ofSphingobacterium sp.

A 50 ml medium (pH 7.0) containing 5 g of glucose, 5 g of ammoniumsulfate, 1 g of monopotassium phosphate, 3 g of dipotassium phosphate,0.5 g of magnesium sulfate, 10 g of yeast extract, and 10 g of peptonein 1 L was transferred to a 500 mL Sakaguchi flask and sterilized at115° C. for 15 minutes for culturing Sphingobacterium sp. strain FERMBP-8124 (Depositary institution: the independent administrativecorporation, National Institute of Advanced Industrial Science andTechnology, International Patent Organism Depositary, Address ofdepositary institution: Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi,Ibaraki-ken, Japan, International deposit date: Jul. 22, 2002). This wasthen inoculated with one loopful cells of Sphingobacterium sp. strainFERM BP-8124 (Depositary institution: the independent administrativecorporation, National Institute of Advanced Industrial Science andTechnology, International Patent Organism Depositary, Address ofdepositary institution: Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi,Ibaraki-ken, Japan, International deposit date: Jul. 22, 2002) culturedat 30° C. for 24 hours in a slant agar medium (agar: 20 g/L, pH 7.0)containing 5 g of glucose, 10 g of yeast extract, 10 g of peptone and 5g of NaCl in 1 L, followed by shake culturing at 30° C. for 20 hours and120 strokes/minute. 1 ml of this culture broth was then added to theaforementioned medium (50 ml/500 mL Sakaguchi flask) and cultured at 30°C. for 18 hours. Following completion of the culturing, the microbialcells were separated from the culture broth by centrifugation andsuspended in 0.1 M borate buffer (pH 9.0) containing 10 mM EDTA at aconcentration of 100 g/L as wet microbial cells. 0.1 mL of 100 mM boratebuffer (pH 9.0) containing 10 mM EDTA, 200 mM L-alanyl methyl esterhydrochloride and 400 mM L-glutamine was then added to 0.1 mL of thismicrobial cell suspension. The resulting 0.2 mL of mixture was allowedto react at 25° C. for 120 minutes. The concentration ofL-alanyl-L-glutamine formed at this time was 62 mM.

Example 22 Purification of Enzyme from Sphingobacterium sp.

The following procedure after centrifugation was carried out either onice or at 4° C. Sphingobacterium sp. strain FERM BP-8124 (Depositaryinstitution: the independent administrative corporation, NationalInstitute of Advanced Industrial Science and Technology, InternationalPatent Organism Depositary, Address of depositary institution: ChuoDai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan,International deposit date: Jul. 22, 2002) was cultured in the samemanner as Example 21, and the microbial cells were collected bycentrifugation (10,000 rpm, 15 minutes). After washing 2 g of microbialcells with 20 mM Tris-HCl buffer (pH 7.6), they were suspended in 8 mlof the same buffer and subjected to ultrasonic disrupting treatment for45 minutes at 195 W. This ultrasonically disrupted liquid was thencentrifuged (10,000 rpm, 30 minutes) to remove the cell debris andobtain an ultrasonically disrupted liquid supernatant. Thisultrasonically disrupted liquid supernatant was dialyzed overnightagainst 20 mM Tris-HCl buffer (pH 7.6) followed by removal of theinsoluble fraction by ultracentrifugation (50,000 rpm, 30 minutes) toobtain a soluble fraction in the form of the supernatant liquid. Theresulting soluble fraction was applied to a Q-Sepharose HP column(manufactured by Amersham) pre-equilibrated with Tris-HCl buffer (pH7.6), and the active fraction was collected from the non-adsorbedfraction. This active fraction was dialyzed overnight against 20 mMacetate buffer (pH 5.0) followed by removal of the insoluble fraction bycentrifugation (10,000 rpm, 30 minutes) to obtain a dialyzed fraction inthe form of the supernatant liquid. This dialyzed fraction was thenapplied to an SP-Sepharose HP column (manufactured by Amersham)pre-equilibrated with 20 mM acetate buffer (pH 5.0) to obtain the activefraction in which enzyme was eluted at a linear concentration gradientof the same buffer containing 0 to 1 M NaCl.

Example 23 Production of L-Alanyl-L-Glutamine Using Enzyme Fraction

10 μl of the SP-Sepharose HP fraction (about 27 U/ml) purified inExample 22 was added to 90 μl of 111 mM borate buffer (pH 9.0)containing 111 mM L-alanine methyl ester hydrochloride, 222 mML-glutamine and 11 mM EDTA, and allowed to react at 25° C. for 120minutes. As a result, 73 mM of L-alanyl-L-glutamine was formed in theenzyme-added lot. On the other hand, there was scarcely any productionof L-Ala-L-Glu observed in the enzyme-non-added lot, and the productionamount was only about 0.07 mM after reacting for 120 minutes.

Example 24 Substrate Specificity of Enzyme (11)

Substrate specificity was examined for enzyme derived fromSphingobacterium sp. strain FERM BP-8124 (Depositary institution: theindependent administrative corporation, National Institute of AdvancedIndustrial Science and Technology, International Patent OrganismDepositary, Address of depositary institution: Chuo Dai-6, 1-1 Higashi1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, International deposit date:Jul. 22, 2002). 100 μl of 100 mM borate buffer (pH 9.0) containing thevarious carboxy components at a final concentration of 100 mM and thevarious amine components at a final concentration of 150 mM shown inTables 15-1 to 15-4, the SP-Sepharose HP fraction enzyme purified inExample 22 (addition of 0.33 units in the reaction liquid) and 10 mMEDTA were allowed to react at 25° C. for 1.5 hours. The amounts ofvarious peptides formed in this reaction are shown in Table 15. The “+”mark indicates those peptides for which production was confirmed butwhich were unable to be quantified due to the absence of a standard,while “tr” indicates a trace amount. Furthermore, Tween-80 was added tothe reaction system to a final concentration of 0.1% in the case ofusing L-Tyr-OMe. In addition, hydrochloride salts were used for allcarboxy components.

TABLE 15-1 Carboxy Amine Produced component component peptide (mM)L-Ala-OMe Gly L-Ala-Gly 11.1 L-Ala L-Ala-L-Ala 13.1 L-Val L-Ala-L-Val10.9 L-Leu L-Ala-L-Leu 33.0 L-Ile L-Ala-L-Ile 24.7 L-Met L-Ala-L-Met86.9 L-Pro L-Ala-L-Pro 1.5 L-Phe L-Ala-L-Phe 69.5 L-Trp L-Ala-L-Trp 46.0L-Thr L-Ala-L-Thr 47.3 L-Asn L-Ala-L-Asn 52.3 L-Tyr L-Ala-L-Tyr 11.1L-CySH L-Ala-L-CySH + L-Lys L-Ala-L-Lys 71.2 L-Arg L-Ala-L-Arg 72.2L-His L-Ala-L-His 73.6 L-Asp L-Ala-L-Asp 2.3 L-Glu L-Ala-L-Glu 39.1L-Ser L-Ala-L-Ser 43.8 D-Ser L-Ala-D-Ser 3.3 D-Ala-OMe L-Ser D-Ala-L-Ser24.1 D-Ser D-Ala-D-Ser 5.5

TABLE 15-2 Carboxy Amine Produced component component peptide (mM)L-Thr-OMe L-Gln L-Thr-L-Gln 36.1 Gly-OMe Gly-L-Gln 61.1 L-Ser-OMeL-Ser-L-Gln 12.9 L-Val-OMe L-Val-L-Gln 8.2 L-Met-OMe L-Met-L-Gln 32.6L-Ile-OMe L-Ile-L-Gln 6.4 L-Arg-OMe L-Arg-L-Gln 17.2 L-Tyr-OMeL-Tyr-L-Gln 0.6 L-Pro-OMe L-Pro-L-Gln 1.8 L-Phe-OMe L-Phe-L-Gln 0.8L-Gln-OMe L-Gln-L-Gln 0.1 Asp-α-OMe α-L-Asp-L-Gln 0.05

TABLE 15-3 Carboxy Amine Produced component component peptide (mM)L-Thr-OMe Gly L-Thr-Gly 0.4 L-Ala L-Thr-L-Ala 5.8 L-Val L-Thr-L-Val 1.3L-Leu L-Thr-L-Leu 15.3 L-Met L-Thr-L-Met 28.9 Gly-OMe L-Arg Gly-L-Arg17.9 L-Phe Gly-L-Phe 20.0 L-His Gly-L-His 36.2 L-Lys Gly-L-Lys 48.2L-Ser Gly-L-Ser 53.8 L-Ser-OMe L-Ser L-Ser-L-Ser 9.9 L-Met L-Ser-L-Met7.6 L-Phe L-Ser-L-Phe 4.3 L-Val-OMe L-Ser L-Val-L-Ser 31.9 L-MetL-Val-L-Met 6.8 L-Phe L-Val-L-Phe 1.0 L-Met-OMe L-Ser L-Met-L-Ser 25.3L-Met L-Met-L-Met 28.4 L-Phe L-Met-L-Phe 8.9 L-Ile-OMe L-Ser L-Ile-L-Ser17.3 L-Met L-Ile-L-Met 5.1 L-Phe L-Ile-L-Phe 1.5 L-Arg-OMe L-SerL-Arg-L-Ser 2.2 L-Met L-Arg-L-Met tr L-Phe L-Arg-L-Phe tr

TABLE 15-4 Carboxy Amine Produced component component peptide (mM)L-Ala-OMe Gly amide L-Ala-Gly amide 15.1 L-Ala amide L-Ala-L-Ala amide9.2 L-Phe amide L-Ala-Phe amide 27.1 L-Ala-OMe MethylamineL-Ala-methylamine 0.6 L-Thr-OMe L-Thr-methylamine 0.3 Gly-OMeGly-methylamine 1.0 L-Ala amide L-Gln L-Ala-L-Gln 0.3 L-Met L-Ala-L-Mettr L-His L-Ala-L-His tr Hydrochloride salts were used for all the aminoacid amides.

Example 25 Substrate Specificity of Enzyme (12)

Substrate specificity with respect to oligopeptide production wasexamined for enzyme derived from Sphingobacterium sp. strain FERMBP-8124 (Depositary institution: the independent administrativecorporation, National Institute of Advanced Industrial Science andTechnology, International Patent Organism Depositary, Address ofdepositary institution: Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi,Ibaraki-ken, Japan, International deposit date: Jul. 22, 2002). 100 μlof 100 mM borate buffer (pH 9.0) containing the various carboxycomponents at a final concentration of 100 mM and the various aminecomponents at a final concentration of 150 mM shown in Table 16, theSP-Sepharose HP fraction enzyme purified in Example 22 (addition of 0.33units in the reaction liquid) and 10 mM EDTA were allowed to react for1.5 hours at 25° C. The amounts of each oligopeptide formed in thisreaction are shown in Table 16. Furthermore, hydrochloride salts wereused for all carboxy components.

TABLE 16 Carboxy Amine Produced component component peptide (mM)L-Ala-OMe L-Ala L-Ala-L-Ala 25.6 L-Ala-L-Ala L-Ala-L-Ala-L-Ala 41.1L-Ala-L-Ala-L- L-Ala-L-Ala-L-Ala- 30.1 Ala L-Ala L-Ala-L-Ala-L-L-Ala-L-Ala-L-Ala- 22.8 Ala-L-Ala L-Ala-L-Ala Gly-Gly L-Ala-Gly-Gly 33.7Gly-Ala L-Ala-Gly-L-Ala 35.1 L-His-L-Ala L-Ala-L-His-L-Ala 58.0L-Phe-Gly L-Ala-L-Phe-Gly 34.0 L-Leu-L-Ala L-Ala-L-Leu-L-Ala 40.7L-Phe-L-Ala L-Ala-L-Phe-L-Ala 24.8 L-Thr-OMe Gly-Gly L-Thr-Gly-Gly 8.4Gly-OMe L-Ala-L-Tyr Gly-L-Ala-L-Tyr 0.6

Example 26 Substrate Specificity of Enzyme (13)

Substrate specificity was additionally assessed using the same enzymefraction as that used in Example 5.

TABLE 17 Carboxy component (mM) Amine component (mM) Produced peptide(mM) Reaction time (hr) H-Ala-OMe 50 mM H-p-F-Phe-OH 50 mMH-Ala-p-F-Phe-OH 21.9 mM 3 H-Ala-OMe 40 mM H—Cl—F-Phe-OH 40 mMH-Ala-Cl—F-Phe-OH 20.8 mM 3 H-Ala-OMe 40 mM H-p-NO₂-Phe-OH 40 mMH-Ala-p-NO₂-Phe-OH 27.5 mM 3 H-Ala-OMe 100 mM H-t-Leu-OH 150 mMH-Ala-t-Leu-OH  0.4 mM 3 H-Ala-OMe 20 mM H-2-Nal-OH 20 mMH-Ala-2-Nal-OH + 3 H-p-F-Phe-OMe 100 mM H-Gln-OH 150 mMH-p-F-Phe-H-Gln-OH tr 3 H-Cl—F-Phe-OMe 25 mM H-Gln-OH 50 mMH—Cl—F-Phe-H-Gln-OH tr 3 H-p-NO₂-Phe-OMe 40 mM H-Gln-OH 40 mMH-p-NO₂-Phe-H-Gln-OH  1.1 mM 3 H-t-Leu-OMe 100 mM H-Gln-OH 150 mMH-t-Leu-H-Gln-OH tr 3 H-2-Nal-OMe 40 mM H-Gln-OH 40 mM H-2-Nal-H-Gln-OHtr 3 H-Aib-OMe 100 mM H-Gln-OH 150 mM H-Aib-H-Gln-OH 18.8 mM 3H—N—Me-Ala-OMe 100 mM H-Gln-OH 150 mM H—N—Me-Ala-H-Gln-OH  0.5 mM 3H-Aib-OMe 100 mM H-Phe-OH 150 mM H-Aib-Phe-OH 17.2 mM 3 H-CHA-OMe 40 mMH-Phe-OH 40 mM H-CHA-Phe-OH + 3 H—N—Me-Ala-OMe 100 mM H-Phe-OH 150 mMH—N—Me-Ala-Phe-OH tr 3 H-Ala-OMe 100 mM H-Ser(tBu)—OH 150 mMH-Ala-Ser(tBu)—OH 48.8 mM 2 H-Ser(tBu)—OMe 100 mM H-Gln-OH 150 mMH-Ser(tBu)-Gln-OH tr 2 H-Ala-OMe 100 mM H-Asp(OtBu)—OH 150 mMH-Ala-Asp(OtBu)—OH 62.6 mM 2 H-Asp(OtBu)—OMe 100 mM H-Gln-OH 150 mMH-Asp(OtBu)-Gln-OH  0.9 mM 2 H-Ala-OMe 100 mM H-Lys(Boc)—OH 150 mMH-Ala-Lys(Boc)—OH 51.0 mM 2 H-Lys(Boc)—OMe 100 mM H-Gln-OH 150 mMH-Lys(Boc)-Gln-OH + 2

100 μl of reaction solutions consisting of 100 mM borate buffer (pH 9.0)containing each of the carboxy components and amine components at thefinal concentrations shown in Table 17, enzyme (addition of 0.1 unit inreaction solution) and 10 mM EDTA were allowed to react at 25° C. forthe reaction times shown in Table 17. The amounts of various peptidesformed in the reactions are shown in Table 17. The “+” mark indicatesthose for which production was confirmed but which were unable to bequantified due to the absence of a standard, while “tr” indicates atrace amount.

Abbreviations

H-Ala-OMe: L-alanine methyl ester hydrochlorideH-p-F-Phe-OMe: p-fluoro-L-phenylalanine methyl ester hydrochlorideH-Cl-F-Phe-OMe: p-chloro-L-phenylalanine methyl ester hydrochlorideH-p-NO₂-Phe-OMe: p-nitro-L-phenylalanine methyl ester hydrochlorideH-t-Leu-OMe: tert-L-leucine methyl ester hydrochlorideH-2-NaI-OMe: 3-(2-naphthyl)-L-alanine methyl ester hydrochlorideH-Aib-OMe: α-aminoisobutyric acid methyl ester hydrochlorideH-N-Me-Ala-OMe: N-methyl-L-alanine methyl ester hydrochlorideH-CHA-OMe: β-cyclohexyl-L-alanine methyl ester hydrochlorideH-Ser(tBu)-OMe: O-tert-butyl-L-serine methyl ester hydrochlorideH-Asp(OtBu)-OMe: L-aspartic acid β-tert-butyl ester a-methyl esterhydrochlorideH-Lys(Boc)-OMe: N-ε-tert-butoxycarbonyl-L-lysine methyl esterhydrochlorideH-p-F-Phe-OH: p-fluoro-L-phenylalanineH-Cl-F-Phe-OH: p-chloro-L-phenylalanineH-p-NO₂-Phe-OH: p-nitro-L-phenylalanineH-t-Leu-OH: tert-L-leucineH-2-Nal-OH: 3-(2-naphthyl)-L-alanine

H-Gln-OH: L-glutamine H-Phe-OH: L-phenylalanine H-Ser(tBu)-OH:O-tert-butyl-L-serine

H-Asp(OtBu)-OH: L-aspartic acid β-tert-butyl ester

H-Lys(Boc)-OH: N-c-tert-butoxycarbonyl-L-lysine Example 27 SubstrateSpecificity of Enzyme (14)

Substrate specificity with respect to oligopeptide production wasassessed using the same enzyme fraction as Example 5 (derived fromEmpedobacter brevis). 100 μl of reaction solutions consisting of 100 mMborate buffer (pH 9.0) containing each of the carboxy components andamine components at the final concentrations shown in Table 18, enzyme(the numbers of units added to the reaction solution are described inTable 18) and 10 mM EDTA were allowed to react at 25° C. for 3 hours.The amounts of various oligopeptides formed in the reactions are shownin Table 18. A “+” mark indicates those for which production wasconfirmed but which were unable to be quantified due to the absence of astandard, while “tr” indicates a trace amount. It should be noted thathydrochloride salts were used for all the carboxy components.

TABLE 18 Amount of Carboxy Amine enzyme Produced component component(unit) peptide (mM) Gly-OMe L-Phe-L-Met 1.0 Gly-Phe-Met 13.3 L-Ala-OMeL-Phe-L-Met 0.2 L-Ala-L-Phe-L-Met + L-Tyr-OMe Gly-Gly-L- 1.0L-Tyr-Gly-Gly-  2.7 Phe-L-Met L-Phe-L-Met L-Ala-OMe Gly-Gly-L- 0.2L-Ala-Gly-Gly- + Phe-L-Met L-Phe-L-Met Gly-OMe Gly-L-Phe 0.1 Gly-L-Phe17.3 L-Ala-OMe Gly-L-Phe 0.1 L-Ala-Gly-L-Phe + D-Ala-OMe Gly-L-Phe 0.1D-Ala-Gly-L-Phe Tr

Example 28 Isolation of Peptide-Forming Enzyme Gene Derived fromEmpedobacter brevis

Hereinafter, although the following provides a description of theisolation of a peptide-forming enzyme gene, will be explained. As themicrobe was used Empedobacter brevis strain FERM BP-8113 (Depositaryinstitution: the independent administrative corporation, NationalInstitute of Advanced Industrial Science and Technology, InternationalPatent Organism Depositary, Address of depositary institution: ChuoDai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan,International deposit transfer date: Jul. 8, 2002) was used as themicrobe. In isolating the gene, Escherichia coli JM-109 was used as ahost while pUC118 was used as a vector.

(1) Production of PCR Primer Based on Determined Internal Amino AcidSequence

A mixed primer having the base sequences indicated in SEQ ID NO.: 3 andSEQ ID NO: 4, respectively, was produced based on the amino acidsequences (SEQ ID NOs: 1 and 2) determined according to the Edman'sdecomposition method from the a digestion product of lysyl endopeptidaseof a peptide-forming enzyme derived from the Empedobacter brevis strainFERM BP-8113 (Depositary institution: the independent administrativecorporation, National Institute of Advanced Industrial Science andTechnology, International Patent Organism Depositary, Address ofdepositary institution: Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi,Ibaraki-ken, Japan, International deposit transfer date: Jul. 8, 2002)digested by a lysyl endopeptidase.

(2) Preparation of Microbial Cells

Empedobacter brevis strain FERM BP-8113 (Depositary institution: theindependent administrative corporation, National Institute of AdvancedIndustrial Science and Technology, International Patent OrganismDepositary, Address of depositary institution: Chuo Dai-6, 1-1 Higashi1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, International deposit transferdate: Jul. 8, 2002) was cultured at 30° C. for 24 hours on a CM2G agarmedium (containing glucose at 50 g/l, yeast extract at 10 g/l, peptoneat 10 g/l, sodium chloride at 5 g/l, and agar at 20 g/l, pH 7.0). Oneloopful of the resulting microbial cells was inoculated into a 500 mlSakaguchi flask containing 50 ml of a CM2G liquid medium (theaforementioned medium excluding agar) followed by shake culturing at 30°C.

(3) Preparation of Chromosomal DNA from Microbial Cells

First, 50 ml of culture broth was centrifuged (12,000 rpm, 4° C., 15minutes) to collect the microbial cells. Then, a chromosomal DNA wasobtained from the microbial cells using the QIAGEN Genomic-Tip System(Qiagen) based on the procedure described in the manual therefor.

(4) Preparation of DNA Fragment Containing Part of Peptide-FormingEnzyme Gene by PCR

A DNA fragment containing a portion of the peptide-forming enzyme genederived from Empedobacter brevis strain FERM BP-8113 (Depositaryinstitution: the independent administrative corporation, NationalInstitute of Advanced Industrial Science and Technology, InternationalPatent Organism Depositary, Address of depositary institution: Dai-6,1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, Internationaldeposit transfer date: Jul. 8, 2002) was obtained by the PCR methodusing LA-Taq (manufactured by Takara Shuzo). A PCR reaction was thencarried out on a chromosomal DNA obtained from Empedobacter brevisstrain FERM BP-8113 (Depositary institution: the independentadministrative corporation, National Institute of Advanced IndustrialScience and Technology, International Patent Organism Depositary,Address of depositary institution: Chuo Dai-6, 1-1 Higashi 1-Chome,Tsukuba-shi, Ibaraki-ken, Japan, International deposit transfer date:Jul. 8, 2002) using the primers having the base sequences of SEQ ID NOs:3 and 4.

The PCR reaction was carried out for 30 cycles under the followingconditions using the Takara PCR Thermal Cycler PERSONAL (manufactured byTakara Shuzo).

94° C. 30 seconds 52° C. 1 minute 72° C. 1 minute

After the reaction, 3 μl of the reaction liquid was applied to 0.8%agarose electrophoresis. As a result, it was verified that a DNAfragment of about 1.5 kilobases (kb) was confirmed to be amplified.

(5) Cloning of Peptide-Forming Enzyme Gene from Gene Library

In order to obtain the entire length of peptide-forming enzyme gene infull-length, Southern hybridization was carried out using the DNAfragment amplified in the PCR procedure as a probe. The procedure forSouthern hybridization is explained in Molecular Cloning, 2nd edition,Cold Spring Harbor Press (1989).

The approximately 1.5 kb DNA fragment amplified by the PCR procedure wasisolated by 0.8% agarose electrophoresis. The target band was then cutout and the DNA fragment was purified. The DNA fragment was labeled withprobe digoxinigen using DIG High Prime (manufactured byBoehringer-Mannheim) based on the procedure described in the manual ofthe kit.

After completely digesting the chromosomal DNA of Empedobacter brevisobtained in the step (3) of the present Example 28(3) by reacting at 37°C. for 16 hours with restriction enzyme HindIII, the resultant DNA waselectrophoresed with on 0.8% agarose gel. The electrophoresedchromosomal DNA was blotted onto a positively charged Nylon membranefilter (manufactured by Roche Diagnostics) from the agarose gel afterthe electrophoresis, followed by treatments consisting of alkalinedenaturation, neutralization and immobilization. Hybridization wascarried out using EASY HYB (manufactured by Boehringer-Mannheim). Afterpre-hybridizing the filter at 50° C. for 1 hour, the probe labeled withdigoxinigen prepared as described above was added and hybridization wascarried out at 50° C. for 16 hours. Subsequently, the filter was washedfor 20 minutes at room temperature with 2×SSC containing 0.1% SDS.Moreover, the filter was additionally washed twice at 65° C. for 15minutes with 0.1×SSC.

Detection of bands that hybridized with the probe was carried out usingthe DIG Nucleotide Detection Kit (manufactured by Boehringer-Mannheim)based on the procedure described in the manual of the kit. As a result,a roughly 4 kb band was able to be detected that hybridized with theprobe.

Then, the chromosomal DNA prepared in the step (3) of the presentExample 28(3) was completely digested with HindIII. A roughly 4 kb ofDNA was separated by 0.8% agarose gel electrophoresis, followed bypurification of the DNA using the Gene Clean II Kit (manufactured byFunakoshi) and dissolving the DNA in 10 μl of TE. 4 μl of this productwas then mixed with pUC118 HindIII/BAP (manufactured by Takara Shuzo)and a ligation reaction was carried out using the DNA Ligation Kit Ver.2 (manufactured by Takara Shuzo). 5 μl of the ligation reaction mixtureand 100 μl of competent cells of Escherichia coli JM109 (manufactured byToyobo) were mixed to transform the Escherichia coli. Thus obtainedtransformants were then applied to a suitable solid medium to produce achromosomal DNA library.

To obtain the entire full-length of peptide-forming enzyme gene, thechromosomal DNA library was screened by colony hybridization using theaforementioned probe. The procedure for colony hybridization isexplained in Molecular Cloning, 2nd edition, Cold Spring Harbor Press(1989).

The colonies of the chromosomal DNA library were transferred to a Nylonmembrane filter (Nylon Membrane for Colony and Plaque Hybridization,(manufactured by Roche Diagnostics) followed by treatments consisting ofalkali denaturation, neutralization and immobilization. Hybridizationwas carried out using EASY HYB (manufactured by Boehringer-Mannheim).After pre-hybridizing the filter at 37° C. for 1 hour, theaforementioned probe labeled with digoxinigen was added, followed byhybridization at 50° C. for 16 hours. Subsequently, the filter waswashed for 20 minutes at room temperature with 2×SSC containing 0.1%SDS. Moreover, the filter was additionally washed twice at 65° C. for 15minutes with 0.1×SSC.

Detection of colonies that hybridized with the labeled probe was carriedout using the DIG Nucleotide Detection Kit (manufactured byBoehringer-Mannheim) based on the explanation described in the manual ofthe kit. As a result, two colonies were verified to hybridize with thelabeled probe.

(6) Base Sequence of Peptide-Forming Enzyme Gene Derived fromEmpedobacter brevis

Plasmids possessed by Escherichia coli JM109 were prepared from theaforementioned two colonies that were verified to hybridize with thelabeled probe using the Wizard Plus Minipreps DNA Purification System(manufactured by Promega) to and the base sequence of a portion wherehybridization with the probe occurred and nearby was determined. Thesequencing reaction was carried out using the CEQ DTCS-Quick Start Kit(manufactured by Beckman-Coulter) based on the procedure described inthe manual of the kit. In addition, electrophoresis was carried outusing the CEQ 2000-XL (manufactured by Beckman-Coulter).

As a result, it was verified that an open reading frame that encodes aprotein containing the internal amino acid sequences of thepeptide-forming enzyme (SEQ ID NOs: 1 and 2) did exist. Thus, the openreading frame was confirmed to be a gene encoding the peptide-formingenzyme. The base sequence of the full-length of the peptide-formingenzyme genes along with the corresponding amino acid sequences is shownin SEQ ID NO: 5. As a result of analysis on the homology of theresulting open reading frame with the BLASTP program, homology wasdiscovered between the two enzymes; it showed with a homology of 34% asat the amino acid sequence level exhibited with the α-amino acid esterhydrolase of Acetobacter pasteurianus (see Appl. Environ. Microbiol.,68(1), 211-218 (2002), and a homology of 26% at the amino acid sequencelevel exhibited with the glutaryl-7ACA acylase of Brevibacilluslaterosporum (see J. Bacteriol., 173(24), 7848-7855 (1991).

Example 29 Expression of Peptide-Forming Enzyme Gene Derived fromEmpedobacter brevis in Escherichia coli

A target gene region on the promoter region of the trp operon on thechromosomal DNA of Escherichia coli W3110 was amplified by carrying outPCR using the oligonucleotides indicated in SEQ ID NOs: 7 and 8 asprimers, and the resulting DNA fragments were ligated to a pGEM-Teasyvector (manufactured by Promega). E. coli JM109 was then transformed inthis ligation solution, and those strains having the target plasmid inwhich the direction of the inserted trp promoter is inserted in theopposite to the orientation from of the lac promoter were selected fromampicillin-resistant strains. Next, a DNA fragment containing the trppromoter obtained by treating this plasmid with EcoO109I/EcoRI wasligated to an EcoO109I/EcoRI treatment product of pUC19 (manufactured byTakara). Escherichia coli JM109 was then transformed with this ligationsolution and those strains having the target plasmid were selected fromampicillin-resistant strains. Next, a DNA fragment obtained by treatingthis plasmid with HindIII/PvuII was ligated with to a DNA fragmentcontaining an rrnB terminator obtained by treating pKK223-3(manufactured by Amersham Pharmacia) with HindIII/HincII. E. coli JM109was then transformed with this ligation solution, strains having thetarget plasmid were selected from ampicillin-resistant strains, and theplasmid was designated as pTrpT.

The target gene was amplified by PCR using the chromosomal DNA ofEmpedobacter brevis strain FERM BP-8113 (Depositary institution: theindependent administrative corporation, National Institute of AdvancedIndustrial Science and Technology, International Patent OrganismDepositary, Address of depositary institution: Chuo No Chuo Dai-6, 1-1Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, International deposittransfer date: Jul. 8, 2002) as a template and the oligonucleotidesindicated in SEQ ID NO: 9 and 10 as primers. This DNA fragment was thentreated with NdeI/PstI, and the resulting DNA fragment was ligated withthe NdeI/PstI treatment product of pTrpT. Escherichia coli JM109 wasthen transformed with this ligation solution, those strains having thetarget plasmid were selected from ampicillin-resistant strains, and thisplasmid was designated as pTrpT_Gtg2.

Escherichia coli JM109 having pTrpT_Gtg2 was pre-cultured at 30° C. for24 hours in LB medium containing 100 mg/l of ampicillin. 1 ml of theresulting culture broth was inoculated into a 500 ml Sakaguchi flaskcontaining 50 ml of a medium (D glucose at 2 g/l, yeast extract at 10g/l, casamino acids at 10 g/l, ammonium sulfate at 5 g/l, potassiumdihydrogen phosphate at 3 g/l, dipotassium hydrogen phosphate at 1 g/l,magnesium sulfate heptahydrate at 0.5 g/l, and ampicillin at 100 mg/l),followed by culturing at 25° C. for 24 hours. The culture broth had anL-alanyl-L-glutamine forming activity of 0.44 U per 1 ml of culturebroth and it was verified that the cloned gene was expressed by E. coli.Furthermore, no activity was detected for a transformant in which onlypTrpT had been introduced as a control.

Prediction of Signal Sequence

When the amino acid sequence of SEQ ID NO: 6 described in the SequenceListing was analyzed with the Signal P v 1.1 program (see ProteinEngineering, Vol. 12, No. 1, pp. 3-9, 1999), it was predicted that aminoacids numbers 1 to 22 function as a signal for secretion of peptide intothe periplasm, while the mature protein was estimated to be downstreamof amino acid number 23.

Verification of Secretion

Escherichia coli JM109, having pTrpT_Gtg2, was pre-cultured at 30° C.for 24 hours in LB medium containing 100 mg/l of ampicillin. 1 ml of theresulting culture broth was inoculated into a 500 ml Sakaguchi flaskcontaining 50 ml of medium (glucose at 2 g/l, yeast extract at 10 g/l,casamino acids at 10 g/l, ammonium sulfate at 5 g/l, potassiumdihydrogen phosphate at 3 g/l, dipotassium hydrogen phosphate at 1 g/l,magnesium sulfate heptahydrate at 0.5 g/l, and ampicillin at 100 mg/l),followed by final culturing at 25° C. for 24 hours to obtain microbialcells.

The cultured microbial cells were fractionated into a periplasm fractionand a cytoplasm fraction after disruption of cells by an osmoticpressure shock method using a 20 grams/deciliter (g/dl) sucrosesolution. The disrupted microbial cells immersed in the 20 g/dl sucrosesolution were immersed in a 5 mM aqueous MgSO₄ solution. The centrifugedsupernatant was named a periplasm fraction (“Pe”). In addition, thecentrifuged sediment was re-suspended and subjected to ultrasonicdisruption. The resultant was named a cytoplasm fraction (“Cy”). Theactivity of glucose 6-phosphate dehydrogenase, which is known to bepresent in the cytoplasm, was used as an indicator to verify that thecytoplasm had been separated. This measurement was carried out by addinga suitable amount of enzyme to a reaction solution at 30° C. containing1 mM glucose 6-phosphate, 0.4 mM NADP, 10 mM MgSO₄, and 50 mM Tris-Cl(pH 8), followed by measurement of absorbance at 340 nm to measureproduction of NADPH.

FIG. 4 demonstrates that the amounts of enzymes of in the periplasmfraction and the cytoplasm fraction when the activity of a separatelyprepared cell-free extract was assigned a value of 100%. The glucose6-phosphate dehydrogenase activity was not detected in the periplasmfraction. This indicates that the periplasm fraction did not mix in thecytoplasm fraction. About 60% of the Ala-Gln forming activity wasrecovered in the periplasm fraction, and it was verified that theAla-Gln forming enzyme was secreted into the periplasm as predicted fromthe amino acid sequence using the Signal P v 1.1 program.

Example 30 Production of L-Alanyl-L-Glutamine Using Microbial Cells ofSphingobacterium sp.

A 50 ml medium (pH 7.0) containing 5 g of glucose, 5 g of ammoniumsulfate, 1 g of monopotassium phosphate, 3 g of dipotassium phosphate,0.5 g of magnesium sulfate, 10 g of yeast extract, and 10 g of peptonein 1 L was transferred to a 500 mL Sakaguchi flask and sterilized at115° C. for 15 minutes for culturing Sphingobacterium sp. strain FERMBP-8124 (Depositary institution: the independent administrativecorporation, National Institute of Advanced Industrial Science andTechnology, International Patent Organism Depository, Address ofdepositary institution: Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi,Ibaraki-ken, Japan, International deposit date: Jul. 22, 2002). This wasthen inoculated with one loopful cells of Sphingobacterium sp. strainFERM BP-8124 (Depositary institution: National Institute of AdvancedIndustrial Science and Technology, International Patent OrganismDepositary, Address of depositary institution: Chuo Dai-6, 1-1 Higashi1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, International deposit date:Jul. 22, 2002) cultured at 30° C. for 24 hours in slant agar medium(agar: 20 g/L, pH 7.0) containing 5 g of glucose, 10 g of yeast extract,10 g of peptone and 5 g of NaCl in 1 L, followed by shake culturing at30° C. for 20 hours and 120 strokes/minute. 1 ml of this culture brothwas then added to the aforementioned medium (50 ml/500 mL Sakaguchiflask) and cultured at 30° C. for 18 hours. After completion of theculture, the microbial cells were separated from the culture broth bycentrifugation and suspended in 0.1 M borate buffer (pH 9.0) containing10 mM EDTA at a concentration of 100 g/L as wet microbial cells. 0.1 mLof 100 mM borate buffer (pH 9.0) containing 10 mM EDTA, 200 mM L-alaninemethyl ester hydrochloride and 400 mM L-glutamine was then added to 0.1mL of this microbial cell suspension. The resulting 0.2 mL of mixturewas allowed to react at 25° C. for 120 minutes. The concentration ofL-alanyl-L-glutamine produced at this time was 62 mM.

Example 31 Purification of Enzyme from Sphingobacterium sp.

The following procedure after centrifugation was carried out either onice or at 4° C. Sphingobacterium sp. strain FERM BP-8124 (Depositaryinstitution: the independent administrative corporation, NationalInstitute of Advanced Industrial Science and Technology, InternationalPatent Organism Depositary, Address of depositary institution: ChuoDai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan,International deposit date: Jul. 22, 2002) was cultured in the samemanner as Example 21, and the microbial cells were collected bycentrifugation (10,000 rpm, 15 minutes). After washing 2 g of microbialcells with 20 mM Tris-HCl buffer (pH 7.6), they were suspended in 8 mlof the same buffer and subjected to ultrasonic disrupting treatment for45 minutes at 195 W. This ultrasonically disrupted suspension was thencentrifuged (10,000 rpm, 30 minutes) to remove the cell debris andobtain a supernatant. This supernatant was dialyzed overnight against 20mM Tris-HCl buffer (pH 7.6) followed by removal of the insolublefraction by ultracentrifugation (50,000 rpm, 30 minutes) to obtain asoluble fraction in the form of the supernatant liquid. The resultingsoluble fraction was applied to a Q-Sepharose HP column (manufactured byAmersham) pre-equilibrated with Tris-HCl buffer (pH 7.6), and the activefraction was collected from the non-adsorbed fraction. This activefraction was dialyzed overnight against 20 mM acetate buffer (pH 5.0),followed by removal of the insoluble fraction by centrifugation (10,000rpm, 30 minutes) to obtain a dialyzed fraction in the form of thesupernatant liquid. This dialyzed fraction was then applied to anSP-Sepharose HP column (manufactured by Amersham) pre-equilibrated with20 mM acetate buffer (pH 5.0) to obtain the active fraction in whichenzyme was eluted at a linear concentration gradient of the same buffercontaining 0 to 1 M NaCl.

Example 32 Production of L-Alanyl-L-Glutamine Using Active Fraction

10 μl of the SP-Sepharose HP fraction (about 27 U/ml) purified inExample 31 was added to 90 μl of borate buffer (pH 9.0) containing 111mM L-alanine methyl ester hydrochloride, 222 mM L-glutamine and 11 mMEDTA, and allowed to react at 25° C. for 120 minutes. As a result, 73 mMof L-alanyl-L-glutamine was produced in the section to which enzyme wasadded. On the other hand, there was scarcely any production ofL-Ala-L-Glu observed in the lot to which enzyme was not added, and theamount produced was only about 0.07 mM after reacting for 120 minutes.

Example 33 Isolation of Peptide-Forming Enzyme Gene Derived fromSphingobacterium sp.

Although the following provides a description of the isolation of apeptide-forming enzyme gene, Sphingobacterium sp. strain FERM BP-8124(Depositary institution: the independent administrative corporation,National Institute of Advanced Industrial Science and Technology,International Patent Organism Depositary, Address of depositaryinstitution: Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken,Japan, International deposit date: Jul. 22, 2002) was used as themicrobe. Gene isolation was carried out using Escherichia coli DH5α asthe host, and pUC118 as the vector.

(1) Preparation of Microbe

Sphingobacterium sp. strain FERM BP-8124 (Depositary institution: theindependent administrative corporation, National Institute of AdvancedIndustrial Science and Technology, International Patent OrganismDepositary, Address of depositary institution: Chuo Dai-6, 1-1 Higashi1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, International deposit date:Jul. 22, 2002) was cultured at 25° C. for 24 hours on CM2G agar medium(containing glucose at 50 g/l, yeast extract at 10 g/l, peptone at 10g/l, sodium chloride at 5 g/l and agar at 20 g/l, pH 7.0). One loopfulof the resulting microbial cells was inoculated into a 500 ml Sakaguchiflask containing 50 ml of CM2G liquid medium (the aforementioned mediumexcluding agar) followed by shake culturing at 25° C.

(2) Preparation of Chromosomal DNA from Microbial Cells

50 ml of culture broth was centrifuged (12,000 rpm, 4° C., 15 minutes)to collect the microbial cells. A chromosomal DNA was then obtained fromthe microbial cells using the Qiagen Genomic-Tip System (Qiagen)therefor.

(3) Preparation of Probe DNA Fragment by PCR

A DNA fragment containing a portion of the peptide-forming enzyme genederived from Empedobacter brevis strain FERM BP-8113 (Depositaryinstitution: the independent administrative corporation, NationalInstitute of Advanced Industrial Science and Technology, InternationalPatent Organism Depositary, Address of depositary institution: ChuoDai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan,International deposit transfer date: Jul. 8, 2002) was obtained by thePCR method using LA-Taq (manufactured by Takara Shuzo). A PCR reactionwas then carried out on a chromosomal DNA obtained from Empedobacterbrevis strain FERM BP-8113 (Depositary institution: the independentadministrative corporation, National Institute of Advanced IndustrialScience and Technology, International Patent Organism Depositary,Address of depositary institution: Chuo Dai-6, 1-1 Higashi 1-Chome,Tsukuba-shi, Ibaraki 1-Chome, Japan, International deposit transferdate: Jul. 8, 2002) using primers having the base sequences of SEQ IDNOs: 3 and 4.

The PCR reaction was carried out for 30 cycles under the followingconditions using the Takara PCR Thermal Cycler PERSONAL (manufactured byTakara Shuzo).

94° C. 30 seconds 52° C. 1 minute 72° C. 1 minute

After the reaction, 3 μl of reaction mixture was applied to 0.8% agaroseelectrophoresis. As a result, a DNA fragment of about 1.5 kb wasconfirmed to be amplified.

(4) Cloning of Peptide-Forming Enzyme Gene from Gene Library

In order to obtain the entire length of peptide-forming enzyme gene,Southern hybridization was carried out using the DNA fragment amplifiedin the aforementioned PCR procedure as a probe. The procedure forSouthern hybridization is explained in Molecular Cloning, 2nd edition,Cold Spring Harbor Press (1989).

The approximately 1.5 kb DNA fragment amplified by the aforementionedPCR procedure was separated by 0.8% agarose electrophoresis. The targetband was then cut out and the DNA fragment was purified. This DNAfragment was labeled with probe digoxinigen using DIG High Prime(manufactured by Boehringer-Mannheim) based on the procedure describedin the manual of the kit.

After completely digesting the chromosomal DNA of Sphingobacterium sp.obtained in the step (2) of the present Example 33 by reacting at 37° C.for 16 hours with restriction enzyme SacI, it was electrophoresed with0.8% agarose gel. The electrophoresed chromosomal DNA was blotted onto apositively charged Nylon membrane filter (manufactured by RocheDiagnostics) from the agarose gel following electrophoresis followed bytreatment consisting of alkaline denaturation, neutralization andimmobilization. Hybridization was carried out using EASY HYB(manufactured by Boehringer-Mannheim). After pre-hybridizing the filterat 37° C. for 1 hour, the probe labeled with digoxinigen prepared asdescribed above was added and hybridization was carried out at 37° C.for 16 hours. Subsequently, the filter was washed twice at 60° C. with1×SSC containing 0.1% SDS.

Detection of bands that hybridized with the probe was carried out usingthe DIG Nucleotide Detection Kit (manufactured by Boehringer-Mannheim)based on the procedure described in the manual of the kit. As a result,a roughly 3 kb band was able to be detected that hybridized with theprobe.

The chromosomal DNA prepared in the step (2) of the present Example 33was completely digested with SacI. Roughly 3 kb of DNA was separated by0.8% agarose gel electrophoresis, followed by purification of the DNAusing the Gene Clean II Kit (manufactured by Funakoshi) and dissolvingin 10 μl of TE. After allowing 4 μl of this product to react with SacIat 37° C. for 16 hours to completely digest, it was mixed with pUC118treated with alkaline phosphatase (E. coli C75) at 37° C. for 30 minutesand at 50° C. for 30 minutes, and a ligation reaction was carried outusing the DNA Ligation Kit Ver. 2 (manufactured by Takara Shuzo). 5 μlof this ligation reaction liquid and 100 μl of competent cells ofEscherichia coli DH5α (manufactured by Takara Shuzo) were mixed totransform the Escherichia coli. Thus obtained transformants were thenapplied to a suitable solid medium to produce a chromosomal DNA library.

In order to obtain the entire length of peptide-forming enzyme gene, thechromosomal DNA library was screened by colony hybridization using theaforementioned probe. The procedure for colony hybridization isexplained in Molecular Cloning, 2nd edition, Cold Spring Harbor Press(1989).

The colonies of the chromosomal DNA library were transferred to a Nylonmembrane filter—Nylon Membrane for Colony and Plaque Hybridization(manufactured by Roche Diagnostics), followed by treatment consisting ofalkaline denaturation, neutralization and immobilization. Hybridizationwas carried out using EASY HYB (manufactured by Boehringer-Mannheim).After pre-hybridizing the filter at 37° C. for 1 hour, theaforementioned probe labeled with digoxinigen was added followed byhybridizing at 37° C. for 16 hours. Subsequently, the filter was washedtwice at 60° C. with 1×SSC containing 1% SDS.

Detection of colonies that hybridized with the labeled probe was carriedout using the DIG Nucleotide Detection Kit (manufactured byBoehringer-Mannheim) based on the explanation described in the manual ofthe kit. As a result, six strains of colonies were confirmed tohybridize with the labeled probe.

(5) Base Sequence of Peptide-Forming Enzyme Gene Derived fromSphingobacterium sp.

Plasmids possessed by Escherichia coli DH5α were prepared from theaforementioned six strains of microbial cells which were confirmed tohybridize with the labeled probe using the Wizard Plus Minipreps DNAPurification System (manufactured by Promega) to determine the nearbybase sequences that hybridized with the probe. The sequencing reactionwas carried out using the CEQ DTCS-Quick Start Kit (manufactured byBeckman-Coulter) based on the procedure described in the manual of thekit. In addition, electrophoresis was carried out using the CEQ 2000-XL(manufactured by Beckman-Coulter).

As a result, an open reading frame that encodes peptide-forming enzymewas found to exist. The base sequence of the full-length peptide-formingenzyme gene derived from Sphingobacterium sp. along with thecorresponding amino acid sequence is shown in SEQ ID NO: 11. Thepeptide-forming enzyme derived from Sphingobacterium sp. exhibitedhomology of 63.5% at the amino acid sequence level with thepeptide-forming enzyme derived from the aforementioned Empedobacterbrevis (as determined using the BLASTP program).

Example 34 Expression of Peptide-Forming Enzyme Gene Derived fromSphingobacterium sp. in Escherichia coli

The target gene was amplified by carrying out PCR using a chromosomalDNA of Sphingobacterium sp. strain FERM BP-8124 (Depositary institution:the independent administrative corporation, National Institute ofAdvanced Industrial Science and Technology, International PatentOrganism Depositary, Address of depositary institution: Chuo Dai-6, 1-1Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, International depositdate: Jul. 22, 2002) as template and the oligonucleotides shown in SEQID NOs: 13 and 14 as primers. This DNA fragment was treated withNdeI/XbaI, and the resulting DNA fragment and NdeI/XbaI treatmentproduct of pTrpT were ligated. Escherichia coli JM109 was thentransformed with this ligation solution, strains having the targetplasmid were selected from ampicillin-resistant strains, and the plasmidwas designated as pTrpT_Sm_aet.

Escherichia coli JM109 having pTrpT_Sm_aet was cultured at 25° C. for 20hours by inoculating one loopful cells of the strain into an ordinarytest tube containing 3 ml of medium (glucose at 2 g/l, yeast extract at10 g/l, casamino acids at 10 g/l, ammonium sulfate at 5 g/l, potassiumdihydrogen phosphate at 3 g/l, dipotassium hydrogen phosphate at 1 g/l,magnesium sulfate heptahydrate at 0.5 g/l and ampicillin at 100 mg/l).Cloned gene having L-alanyl-L-glutamine production activity of 2.1 U per1 ml of culture liquid was confirmed to be expressed by E. coli.Furthermore, activity was not detected for a transformant containingonly pTrpT used as a control.

Prediction of Signal Sequence

When the amino acid sequence of SEQ ID NO: 12 described in the SequenceListing was analyzed with the Signal P v1.1 program (see ProteinEngineering, Vol. 12, No. 1, pp. 3-9, 1999), it was predicted that aminoacids numbers 1 to 20 function as a signal for secretion of peptide intothe periplasm, while the mature protein was estimated to be downstreamof amino acid number 21.

Confirmation of Signal Sequence

Escherichia coli JM109, having pTrpT_Sm_aet, was cultured at 25° C. for20 hours by inoculating one loopful cells of the strain into an ordinarytest tube containing 50 ml of medium (glucose at 2 g/l, yeast extract at10 g/l, casamino acids at 10 g/l, ammonium sulfate at 5 g/l, potassiumdihydrogen phosphate at 3 g/l, dipotassium hydrogen phosphate at 1 g/l,magnesium sulfate heptahydrate at 0.5 g/l and ampicillin at 100 mg/l).

The following procedure after centrifugation was carried out either onice or at 4° C. Following completion of culturing, the microbial cellswere separated from the culture broth by centrifugation, and afterwashing with 100 mM phosphate buffer (pH 7), were suspended in the samebuffer. The microbial cells were then subjected to ultrasonic disruptionfor 20 minutes at 195 W, the ultrasonically disrupted liquid wascentrifuged (12,000 rpm, 30 minutes) to remove the cell debris andobtain a soluble fraction. The resulting soluble fraction was applied toa CHT-II column (manufactured by Biorad) pre-equilibrated with 100 mMphosphate buffer (pH 7), and enzyme was eluted at a linear concentrationgradient by 500 mM phosphate buffer. A solution obtained by mixing theactive fraction with a 5-fold volume of 2 M ammonium sulfate and 100 mMphosphate buffer was applied to a Resource-PHE column (Amersham)pre-equilibrated with 2 M ammonium sulfate and 100 mM phosphate buffer,and enzyme was eluted at a linear concentration gradient by 2 to 0 Mammonium sulfate to obtain an active fraction solution. As a result ofthese procedures, the peptide-forming enzyme was confirmed to beuniformly purified in terms of electrophoresis.

When the amino acid sequence of the aforementioned peptide-formingenzyme was determined by Edman's decomposition method, the amino acidsequence of SEQ ID NO: 15 was obtained, and the mature protein wasconfirmed to be downstream from amino acid number 21 as was predicted bythe SignalP v 1.1 program.

Example 35 Isolation of Peptide-Forming Enzyme Gene Derived fromPedobacter heparinus IFO 12017

Hereinafter, the isolation of a peptide-forming enzyme gene will bedescribed. The microbe used is Pedobacter heparinus strain IFO 12017(Depositary institution: Institute of Fermentation, Address ofdepositary institution: 2-17-85 Jusanbon-cho, Yodogawa-ku, Osaka-shi,Japan). Escherichia coli JM-109 was used as a host while pUC118 was usedas a vector in isolating the gene.

(1) Preparation of Microbe

Pedobacter heparinus strain IFO-12017 (Depositary institution: Instituteof Fermentation, Address of depositary institution: 2-17-85Jusanbon-cho, Yodogawa-ku, Osaka-shi, Japan) was cultured at 25° C. for24 hours on CM2G agar medium (containing glucose at 50 g/l, yeastextract at 10 g/l, peptone at 10 g/l, sodium chloride at 5 g/l and agarat 20 g/l, pH 7.0). One loopful of the resulting microbial cells wereinoculated into a 500 ml Sakaguchi flask containing 50 ml of CM2G liquidmedium (the aforementioned medium excluding agar) followed by shakeculturing at 25° C.

(2) Preparation of Chromosomal DNA from Microbial Cells

50 ml of culture broth was centrifuged (12,000 rpm, 4° C., 15 minutes)to collect the microbial cells. A chromosomal DNA was then obtained fromthe microbial cells using the Qiagen Genomic-Tip System (Qiagen) basedon the procedure described in the manual therefor.

(3) Preparation of Probe DNA Fragment by PCR

A DNA fragment containing a portion of the peptide-forming enzyme genederived from Pedobacter heparinus strain IFO-12017 (Depositaryinstitution: Institute of Fermentation, Address of depositaryinstitution: 2-17-85 Jusanbon-cho, Yodogawa-ku, Osaka-shi, Japan) wasobtained by the PCR method using LA-Taq (manufactured by Takara Shuzo).A PCR reaction was then carried out on a chromosomal DNA obtained fromPedobacter heparinus strain IFO-12017 (Depositary institution: Instituteof Fermentation, Address of depositary institution: 2-17-85Jusanbon-cho, Yodogawa-ku, Osaka-shi, Japan) using primers having thebase sequences of SEQ ID NOs: 15 and 16. A DNA fragment of about 1 kbamplified by PCR was separated by 0.8% agarose electrophoresis. Thetarget band was then cut out and thus obtained DNA fragment waspurified. This DNA fragment was labeled with probe digoxinigen using DIGHigh Prime based on the procedure described in the manual (manufacturedby Boehringer-Mannheim).

(4) Cloning of Peptide-Forming Enzyme Gene from Gene Library

To obtain the full-length peptide-forming enzyme gene, Southernhybridization was carried out using the DNA fragment amplified in theaforementioned PCR procedure as a probe. The procedure for Southernhybridization is explained in Molecular Cloning, 2nd edition, ColdSpring Harbor Press (1989).

After completely digesting the chromosomal DNA of Pedobacter heparinusstrain IFO-12017 (Depositary institution: Institute of Fermentation,Address of depositary institution: 2-17-85 Jusanbon-cho, Yodogawa-ku,Osaka-shi, Japan) by reacting at 37° C. for 16 hours with restrictionenzyme HindIII, it was electrophoresed with 0.8% agarose gel. Theelectrophoresed chromosomal DNA was blotted onto a positively chargedNylon membrane filter (manufactured by Roche Diagnostics) from theagarose gel after the electrophoresis, followed by treatment consistingof alkali denaturation, neutralization, and immobilization.Hybridization was carried out using EASY HYB (manufactured byBoehringer-Mannheim). After pre-hybridizing the filter at 50° C. for 1hour, the probe labeled with digoxinigen prepared as described above wasadded and hybridization was carried out at 50° C. for 16 hours.Subsequently, the filter was washed twice at 60° C. with 1×SSCcontaining 0.1% SDS.

Detection of bands that hybridized with the probe was carried out basedon the procedure described in the manual using the DIG NucleotideDetection Kit (manufactured by Boehringer-Mannheim). As a result, aroughly 5 kb band was able to be detected that hybridized with theprobe.

The chromosomal DNA of Pedobacter heparinus strain IFO-12017 (Depositaryinstitution: Institute of Fermentation, Address of depositaryinstitution: 2-17-85 Jusanbon-cho, Yodogawa-ku, Osaka-shi, Japan) werecompletely digested with HindIII. Roughly 5 kb of DNA were separated by0.8% agarose gel electrophoresis followed by purification of the DNAusing the Gene Clean II Kit (manufactured by Funakoshi) and dissolvingin 10 μl of TE. 4 μl of this product was then mixed with pUC118HindIII/BAP (manufactured by Takara Shuzo) and a ligation reaction wascarried out using the DNA Ligation Kit Ver. 2 (manufactured by TakaraShuzo). 5 μl of this ligation reaction liquid and 100 μl of competentcells of Escherichia coli JM109 (manufactured by Takara Shuzo) weremixed to transform the Escherichia coli. The obtained transformants werethen applied to a suitable solid medium to produce a chromosomal DNAlibrary.

In order to obtain the full-length peptide-forming enzyme gene, thechromosomal DNA library was screened by colony hybridization using theaforementioned probe. The procedure for colony hybridization isexplained in Molecular Cloning, 2nd edition, Cold Spring Harbor Press(1989).

The colonies of the chromosomal DNA library were transferred to a Nylonmembrane filter, Nylon Membrane for Colony and Plaque Hybridization,(manufactured by Roche Diagnostics), followed by treatment consisting ofalkali denaturation, neutralization and immobilization. Hybridizationwas carried out using EASY HYB (manufactured by Boehringer-Mannheim).After pre-hybridizing the filter at 37° C. for 1 hour, theaforementioned probe labeled with digoxinigen was added followed byhybridizing at 37° C. for 16 hours. Subsequently, the filter was washedtwice at 60° C. with 1×SSC containing 1% SDS.

Detection of colonies that hybridized with the labeled probe was carriedout based on the explanation described in the manual using the DIGNucleotide Detection Kit (manufactured by Boehringer-Mannheim). As aresult, 1 strain of colonies was confirmed to hybridize with the labeledprobe.

(5) Base Sequence of Peptide-Forming Enzyme Gene Derived from Pedobacterheparinus Strain IFO-12017

Plasmids retained by Escherichia coli JM109 were prepared from theaforementioned strain of microbial cells which were confirmed tohybridize with the labeled probe, and the nearby base sequence thathybridized with the probe was determined. The sequencing reaction wascarried out using the CEQ DTCS-Quick Start Kit (manufactured byBeckman-Coulter) based on the procedure described in the manual. Inaddition, electrophoresis was carried out using the CEQ 2000-XL(Beckman-Coulter).

As a result, an open reading frame that encodes peptide-forming enzymewas found to exist. The base sequence of the full-length peptide-formingenzyme gene derived from Pedobacter heparinus strain IFO-12017(Depositary institution: Institute of Fermentation, Address ofdepositary institution: 2-17-85 Jusanbon-cho, Yodogawa-ku, Osaka-shi,Japan), along with the corresponding amino acid sequence, is shown inSEQ ID NO: 17 of the Sequence Listing.

Example 36 Expression of Peptide-Forming Enzyme Gene Derived fromPedobacter heparinus Strain IFO-12017 in E. coli

The target gene was amplified by carrying out PCR using a chromosomalDNA of Pedobacter heparinus strain IFO-12017 (Depositary institution:Institute of Fermentation, Osaka, Address of depositary institution:2-17-85 Jusanbon-cho, Yodogawa-ku, Osaka-shi, Japan) as template and theoligonucleotides shown in SEQ ID NOs: 19 and 20 as primers. This DNAfragment was treated with NdeI/HindIII, and the resulting DNA fragmentand NdeI/HindIII treatment product of pTrpT were ligated. Escherichiacoli JM109 was then transformed with this ligation solution, strainshaving the target plasmid were selected from ampicillin-resistantstrains, and the plasmid was designated as pTrpT_Ph_aet.

Escherichia coli JM109 having pTrpT_Ph_aet was cultured at 25° C. for 20hours by inoculating one loopful cells of the strain into an ordinarytest tube containing 3 ml of medium (glucose at 2 g/l, yeast extract at10 g/l, casamino acids at 10 g/l, ammonium sulfate at 5 g/l, potassiumdihydrogen phosphate at 3 g/l, dipotassium hydrogen phosphate at 1 g/l,magnesium sulfate heptahydrate at 0.5 g/l and ampicillin at 100 mg/l). Acloned gene having L-alanyl-L-glutamine production activity of 0.3 U perml of culture liquid was confirmed to be expressed in E. coli.Furthermore, no activity was detected for a transformant containing onlypTrpT used as a control.

Example 37 Isolation of Peptide-Forming Enzyme Gene Derived fromTaxeobacter gelupurpurascens Strain DSMZ 11116

Hereinafter, the isolation of peptide-forming enzyme gene will bedescribed. The microbe used is Taxeobacter gelupurpurascens strain DSMZ11116 (Depositary institution: Deutche Sammlung von Mikroorganismen undZellkulturen GmbH (German Collection of Microbes and Cell Cultures),Address of depositary institution: Mascheroder Weg 1b, 38124Braunschweig, Germany) was used for the microbe. Escherichia coli JM-109was used as a host while pUC118 was used as a vector in isolating thegene.

(1) Preparation of Microbe

Taxeobacter gelupurpurascens strain DSMZ 11116 (Depositary institution:Deutche Sammlung von Mikroorganismen und Zellkulturen GmbH (GermanCollection of Microbes and Cell Cultures), Address of depositaryinstitution: Mascheroder Weg 1b, 38124 Braunschweig, Germany) wascultured at 25° C. for 24 hours on CM2G agar medium (containing glucoseat 50 g/l, yeast extract at 10 g/l, peptone at 10 g/l, sodium chlorideat 5 g/l and agar at 20 g/l, pH 7.0). One loopful of the resultingmicrobial cells were inoculated into a 500 ml Sakaguchi flask containing50 ml of CM2G liquid medium (the aforementioned medium excluding agar)followed by shake culturing at 25° C.

(2) Preparation of Chromosomal DNA from Microbial Cells

50 ml of culture liquid were centrifuged (12,000 rpm, 4° C., 15 minutes)to collect the microbial cells. A chromosomal DNA was then obtained fromthe microbial cells using the Qiagen Genomic-Tip System (Qiagen) basedon the procedure described in the manual therefor.

(3) Preparation of Probe DNA Fragment by PCR

A DNA fragment containing a portion of the peptide-forming enzyme genederived from Taxeobacter gelupurpurascens strain DSMZ 11116 (Depositaryinstitution: Deutche Sammlung von Mikroorganismen und Zellkulturen GmbH(German Collection of Microbes and Cell Cultures), Address of depositaryinstitution: Mascheroder Weg 1b, 38124 Braunschweig, Germany) wasobtained by the PCR method using LA-Taq (manufactured by Takara Shuzo).A PCR reaction was then carried out on a chromosomal DNA obtained fromTaxeobacter gelupurpurascens strain DSMZ 11116 (Depositary institution:Deutche Sammlung von Mikroorganismen und Zellkulturen GmbH (GermanCollection of Microbes and Cell Cultures), Address of depositaryinstitution: Mascheroder Weg 1b, 38124 Braunschweig, Germany) usingprimers having the base sequences of SEQ ID NOs: 21 and 16. A DNAfragment of about 1 kb amplified by PCR was separated by 0.8% agaroseelectrophoresis. The target band was then cut out and the DNA fragmentwas purified. This DNA fragment was labeled with probe digoxinigen usingDIG High Prime (manufactured by Boehringer-Mannheim) based on theprocedure described in the manual.

(4) Cloning of Peptide-Forming Enzyme Gene from Gene Library

To obtain the full-length peptide-forming enzyme gene, Southernhybridization was carried out using the DNA fragment amplified in theaforementioned PCR procedure as a probe. The procedure for Southernhybridization is explained in Molecular Cloning, 2nd edition, ColdSpring Harbor Press (1989).

After completely digesting the chromosomal DNA of Taxeobactergelupurpurascens strain DSMZ 11116 (Depositary institution: DeutcheSammlung von Mikroorganismen und Zellkulturen GmbH (German Collection ofMicrobes and Cell Cultures), Address of depositary institution:Mascheroder Weg 1b, 38124 Braunschweig, Germany) by reacting at 37° C.for 16 hours with restriction enzyme PstI, it was electrophoresed with0.8% agarose gel. The electrophoresed chromosomal DNA was blotted onto apositively charged Nylon membrane filter (manufactured by RocheDiagnostics) from the agarose gel following electrophoresis followed bytreatment consisting of alkali denaturation, neutralization andimmobilization. Hybridization was carried out using EASY HYB(manufactured by Boehringer-Mannheim). After pre-hybridizing the filterat 50° C. for 1 hour, the probe labeled with digoxinigen prepared asdescribed above was added and hybridization was carried out at 50° C.for 16 hours. Subsequently, the filter was washed twice at 60° C. with1×SSC containing 0.1% SDS.

Detection of bands that hybridized with the probe was carried out basedon the procedure described in the manual using the DIG NucleotideDetection Kit (manufactured by Boehringer-Mannheim). As a result, aroughly 5 kb band was able to be detected that hybridized with theprobe.

The chromosomal DNA of Taxeobacter gelupurpurascens strain DSMZ 11116(Depositary institution: Deutche Sammlung von Mikroorganismen andZellkulturen GmbH (German Collection of Microbes and Cell Cultures),Address of depositary institution: Mascheroder Weg 1b, 38124Braunschweig, Germany) were completely digested with HindIII. Roughly 5kb of DNA were separated by 0.8% agarose gel electrophoresis followed bypurification of the DNA using the Gene

Clean II Kit (manufactured by Funakoshi) and dissolving in 10 μl of TE.4 μl of this product were then mixed with pUC118 PstI/BAP (manufacturedby Takara Shuzo) and a ligation reaction was carried out using the DNALigation Kit Ver. 2 (manufactured by Takara Shuzo). 5 μl of thisligation reaction liquid and 100 μl of competent cells of Escherichiacoli JM109 (manufactured by Takara Shuzo) were mixed to transform theEscherichia coli. Thus obtained transformants were then applied to asuitable solid medium to produce a chromosomal DNA library.

In order to obtain the entire length of peptide-forming enzyme gene, thechromosomal DNA library was screened by colony hybridization using theaforementioned probe. The procedure for colony hybridization isexplained in Molecular Cloning, 2nd edition, Cold Spring Harbor Press(1989).

The colonies of the chromosomal DNA library were transferred to a Nylonmembrane filter, Nylon Membrane for Colony and Plaque Hybridization,(manufactured by Roche Diagnostics) followed by treatment consisting ofalkaline denaturation, neutralization and immobilization. Hybridizationwas carried out using EASY HYB (manufactured by Boehringer-Mannheim).After pre-hybridizing the filter at 37° C. for 1 hour, theaforementioned probe labeled with digoxinigen was added followed byhybridizing at 37° C. for 16 hours. Subsequently, the filter was washedtwice at 60° C. with 1×SSC containing 0.1% SDS.

Detection of colonies that hybridized with the labeled probe was carriedout based on the manual using the DIG Nucleotide Detection Kit(manufactured by Boehringer-Mannheim). As a result, 1 strain of colonieswas confirmed to hybridize with the labeled probe.

(5) Base Sequence of Peptide-Forming Enzyme Gene Derived fromTaxeobacter gelupurpurascens Strain DSMZ 11116

Plasmids retained by Escherichia coli JM109 were prepared from theaforementioned strain of microbial cells which were confirmed tohybridize with the labeled probe, and the nearby base sequence thathybridized with the probe was determined. The sequencing reaction wascarried out using the CEQ DTCS-Quick Start Kit (manufactured byBeckman-Coulter) based on the procedure described in the manual. Inaddition, electrophoresis was carried out using the CEQ 2000-XL(manufactured by Beckman-Coulter).

As a result, an open reading frame that encodes peptide-forming enzymewas found to exist. The base sequence of the entire length of thepeptide-forming enzyme gene derived from Taxeobacter gelupurpurascensstrain DSMZ 11116 (Depositary institution: Deutche Sammlung vonMikroorganismen and Zellkulturen GmbH (German Collection of Microbes andCell Cultures), Address of depositary institution: Mascheroder Weg 1b,38124 Braunschweig, Germany), along with the corresponding amino acidsequence, are shown in SEQ ID NO: 22 of the Sequence Listing.

Example 38 Isolation of Peptide-Forming Enzyme Gene Derived fromCyclobacterium marinum Strain ATCC 25205

Hereinafter, the isolation of peptide-forming enzyme gene will bedescribed. The microbe used is Cyclobacterium marinum strain ATCC 25205(Depositary institution: American Type Culture Collection, Address ofdepositary institution: P.O. Box 1549, Manassas, Va. 20110, the UnitedStates of America). Escherichia coli JM-109 was used as a host whilepUC118 was used for the vector in isolating the gene.

(1) Preparation of Microbial Cells

Cyclobacterium marinum strain ATCC 25205 (Depositary institution:American Type Culture Collection, Address of depositary institution:P.O. Box 1549, Manassas, Va. 20110, the United States of America) wascultured at 25° C. for 24 hours on CM2G agar medium (containing glucoseat 50 g/l, yeast extract at 10 g/l, peptone at 10 g/l, sodium chlorideat 5 g/l and agar at 20 g/l, pH 7.0). One loopful of the resultingmicrobial cells was inoculated into a 500 ml Sakaguchi flask containing50 ml of CM2G liquid medium (the aforementioned medium excluding agar),followed by shake culturing at 25° C.

(2) Preparation of Chromosomal DNA from Microbial Cells

50 ml of culture broth were centrifuged (12,000 rpm, 4° C., 15 minutes)to collect the microbial cells. A chromosomal DNA was then obtained fromthe microbial cells based on the procedure described in the manual usingthe Qiagen Genomic-Tip System (Qiagen).

(3) Preparation of Probe DNA Fragment by PCR

A DNA fragment containing a portion of the peptide-forming enzyme genederived from Cyclobacterium marinum strain ATCC 25205 (Depositaryinstitution: American Type Culture Collection, Address of depositaryinstitution: P.O. Box 1549, Manassas, Va. 20110, the United States ofAmerica) was obtained by the PCR method using LA-Taq (manufactured byTakara Shuzo). A PCR reaction was then carried out on a chromosomal DNAobtained from Cyclobacterium marinum strain ATCC 25205 (Depositaryinstitution: American Type Culture Collection, Address of depositaryinstitution: P.O. Box 1549, Manassas, Va. 20110, the United States ofAmerica) using primers having the base sequences of SEQ ID NOs: 15 and16. A DNA fragment of about 1 kb amplified by PCR was separated by 0.8%agarose electrophoresis. The target band was then cut out and the DNAfragment was purified. This DNA fragment was labeled with probedigoxinigen based on the procedure described in the manual using DIGHigh Prime (manufactured by Boehringer-Mannheim).

(4) Cloning of Peptide-Forming Enzyme Gene from Gene Library

In order to obtain the full-length peptide-forming enzyme gene, Southernhybridization was first carried out using the DNA fragment amplified inthe aforementioned PCR procedure as a probe. The procedure for Southernhybridization is explained in Molecular Cloning, 2nd edition, ColdSpring Harbor Press (1989).

After completely digesting the chromosomal DNA of Cyclobacterium marinumstrain ATCC 25205 (Depositary institution: American Type CultureCollection, Address of depositary institution: P.O. Box 1549, Manassas,Va. 20110, the United States of America) by reacting at 37° C. for 16hours with restriction enzyme HincII, each was electrophoresed with 0.8%agarose gel. The electrophoresed chromosomal DNA was blotted onto apositively charged Nylon membrane filter (manufactured by RocheDiagnostics) from the agarose gel following electrophoresis followed bytreatment consisting of alkali denaturation, neutralization andimmobilization. Hybridization was carried out using EASY HYB(manufactured Boehringer-Mannheim). After pre-hybridizing the filter at50° C. for 1 hour, the probe labeled with digoxinigen prepared asdescribed above was added and hybridization was carried out at 50° C.for 16 hours. Subsequently, the filter was washed twice at 60° C. with1×SSC containing 0.1% SDS.

Detection of bands that hybridized with the probe was carried out basedon the procedure described in the manual using the DIG NucleotideDetection Kit (manufactured by Boehringer-Mannheim). As a result, aroughly 7 k band was able to be detected that hybridized with the probein the PstI digestion product, while a 2 k band was able to be detectedthat hybridized with the probe in the HincII digestion product.

The chromosomal DNA of Cyclobacterium marinum strain ATCC 25205(Depositary institution: American Type Culture Collection, Address ofdepositary institution: P.O. Box 1549, Manassas, Va. 20110, the UnitedStates of America) were completely digested with PstI or HincII. Roughly7 kb or 2 kb of DNA were respectively separated by 0.8% agarose gelelectrophoresis, followed by purification of the DNA using the GeneClean II Kit (Funakoshi) and dissolving in 10 μl of TE. 4 μl of thisproduct were then mixed with pUC118 PstI/BAP (manufactured by TakaraShuzo) or pUC118 Hindi/BAP (manufactured by Takara Shuzo) and a ligationreaction was carried out using the DNA Ligation Kit Ver. 2 (manufacturedby Takara Shuzo). 5 μl of this ligation reaction liquid and 100 μl ofcompetent cells of Escherichia coli JM109 (manufactured by Takara Shuzo)were respectively mixed to transform the Escherichia coli. Thus obtainedtransformants were then applied to a suitable solid medium to produce achromosomal DNA library.

To obtain the full-length peptide-forming enzyme gene, the chromosomalDNA library was screened by colony hybridization using theaforementioned probe. The procedure for colony hybridization isexplained in Molecular Cloning, 2nd edition, Cold Spring Harbor Press(1989).

The colonies of the chromosomal DNA library were transferred to a Nylonmembrane filter, Nylon Membrane for Colony and Plaque Hybridization,(manufactured by Roche Diagnostics), followed by treatment consisting ofalkali denaturation, neutralization, and immobilization. Hybridizationwas carried out using EASY HYB (manufactured by Boehringer-Mannheim).After pre-hybridizing the filter at 37° C. for 1 hour, theaforementioned probe labeled with digoxinigen was added followed byhybridizing at 37° C. for 16 hours. Subsequently, the filter was washedtwice at 60° C. with 1×SSC containing 0.1% SDS.

Detection of colonies that hybridized with the labeled probe was carriedout based on the manual using the DIG Nucleotide Detection Kit(manufactured by Boehringer-Mannheim). As a result, 1 strain of colonieseach was confirmed to hybridize with the labeled probe.

(5) Base Sequence of Peptide-Forming Enzyme Gene Derived fromCyclobacterium marinum Strain ATCC 25205

Plasmids retained by Escherichia coli JM109 were prepared from each ofthe aforementioned strains of microbial cells which were confirmed tohybridize with the labeled probe, and the nearby base sequence thathybridized with the probe was determined. The sequencing reaction wascarried out using the CEQ DTCS-Quick Start Kit (manufactured byBeckman-Coulter) based on the procedure described in the manual of thekit. In addition, electrophoresis was carried out using the CEQ 2000-XL(manufactured by Beckman-Coulter).

As a result, an open reading frame that encodes peptide-forming enzymewas found to exist. The base sequence of the full-length peptide-formingenzyme gene derived from Cyclobacterium marinum strain ATCC 25205(Depositary institution: American Type Culture Collection, Address ofdepositary institution: P.O. Box 1549, Manassas, Va. 20110, the UnitedStates of America), along with the corresponding amino acid sequence, isshown in SEQ ID NO: 24 of the Sequence Listing.

Example 39 Isolation of Peptide-Forming Enzyme Gene Derived fromPsycloserpens burtonensis Strain ATCC 700359

Hereinafter, the isolation of a peptide-forming enzyme gene will beexplained. The microbe used is Psycloserpens burtonensis strain ATCC700359 (Depositary institution: American Type Culture Collection,Address of depositary institution: P.O. Box 1549, Manassas, Va. 20110,the United States of America). Escherichia coli JM-109 was used for thehost while pUC118 was used for the vector in isolating the gene.

(1) Preparation of Microbe

Psycloserpens burtonensis strain ATCC 700359 (Depositary institution:American Type Culture Collection, Address of depositary institution:P.O. Box 1549, Manassas, Va. 20110, the United States of America) wascultured at 10° C. for 24 hours on CM2G agar medium (containing glucoseat 50 g/l, yeast extract at 10 g/l, peptone at 10 g/l, sodium chlorideat 5 g/l and agar at 20 g/l, pH 7.0). One loopful of the resultingmicrobial cells was inoculated into a 500 ml Sakaguchi flask containing50 ml of CM2G liquid medium (the aforementioned medium excluding agar)followed by shake culturing at 10° C.

(2) Preparation of Chromosomal DNA from Microbial Cells

50 ml of culture liquid were centrifuged (12,000 rpm, 4° C., 15 minutes)to collect the microbial cells. A chromosomal DNA was then obtained fromthe microbial cells using the Qiagen Genomic-Tip System (Qiagen) basedon the procedure described in the manual therefor.

(3) Preparation of Probe DNA Fragment by PCR

A DNA fragment containing a portion of the peptide-forming enzyme genederived from Psycloserpens burtonensis strain ATCC 700359 (Depositaryinstitution: American Type Culture Collection, Address of depositaryinstitution: P.O. Box 1549, Manassas, Va. 20110, the United States ofAmerica) was obtained by the PCR method using LA-Taq (manufactured byTakara Shuzo). A PCR reaction was then carried out on a chromosomal DNAobtained from Psycloserpens burtonensis strain ATCC 700359 (Depositaryinstitution: American Type Culture Collection, Address of depositaryinstitution: P.O. Box 1549, Manassas, Va. 20110, the United States ofAmerica) using primers having the base sequences of SEQ ID NOs: 15 and16. A DNA fragment of about 1 kb amplified by PCR was separated by 0.8%agarose electrophoresis. The target band was then cut out and the DNAfragment was purified. This DNA fragment was labeled with probedigoxinigen based on the procedure described in the manual using DIGHigh Prime (manufactured by Boehringer-Mannheim).

(4) Cloning of Peptide-Forming Enzyme Gene from Gene Library

In order to obtain the entire length of peptide-forming enzyme gene,Southern hybridization was carried out using the DNA fragment amplifiedin the aforementioned PCR procedure as a probe. The procedure forSouthern hybridization is explained in Molecular Cloning, 2nd edition,Cold Spring Harbor Press (1989).

After completely digesting the chromosomal DNA of Psycloserpensburtonensis strain ATCC 700359 (Depositary institution: American TypeCulture Collection, Address of depositary institution: P.O. Box 1549,Manassas, Va. 20110, the United States of America) by reacting at 37° C.for 16 hours with restriction enzyme EcoRI, it was electrophoresed with0.8% agarose gel. The electrophoresed chromosomal DNA was blotted onto apositively charged Nylon membrane filter (manufactured by RocheDiagnostics) from the agarose gel following electrophoresis followed bytreatment consisting of alkaline denaturation, neutralization andimmobilization. Hybridization was carried out using EASY HYB(manufactured by Boehringer-Mannheim). After pre-hybridizing the filterat 50° C. for 1 hour, the probe labeled with digoxinigen prepared asdescribed above was added and hybridization was carried out at 50° C.for 16 hours. Subsequently, the filter was washed twice at 60° C. with1×SSC containing 0.1% SDS.

Detection of bands that hybridized with the probe was carried out usingthe DIG Nucleotide Detection Kit (manufactured by Boehringer-Mannheim)based on the procedure described in the manual of the kit. As a result,a roughly 7 kb band was able to be detected that hybridized with theprobe.

The chromosomal DNA of Psycloserpens burtonensis strain ATCC 700359(Depositary institution: American Type Culture Collection, Address ofdepositary institution: P.O. Box 1549, Manassas, Va. 20110, the UnitedStates of America) were completely digested with EcoRI. Roughly 7 kb ofDNA were separated by 0.8% agarose gel electrophoresis followed bypurification of the DNA using the Gene Clean II Kit (manufactured byFunakoshi) and dissolving in 10 μl of TE. 4 μl of this product were thenmixed with pUC118 EcoRI/BAP (manufactured by Takara Shuzo) and aligation reaction was carried out using the DNA Ligation Kit Ver. 2(manufactured by Takara Shuzo). 5 μl of this ligation reaction liquidand 100 μl of competent cells of Escherichia coli JM109 (manufactured byTakara Shuzo) were mixed to transform the Escherichia coli. Thusobtained transformants were then applied to a suitable solid medium toproduce a chromosomal DNA library.

To obtain the full-length peptide-forming enzyme gene, the chromosomalDNA library was screened by colony hybridization using theaforementioned probe. The procedure for colony hybridization isexplained in Molecular Cloning, 2nd edition, Cold Spring Harbor Press(1989).

The colonies of the chromosomal DNA library were transferred to a Nylonmembrane filter, Nylon Membrane for Colony and Plaque Hybridization,(manufactured by Roche Diagnostics), followed by treatment consisting ofalkali denaturation, neutralization, and immobilization. Hybridizationwas carried out using EASY HYB (manufactured by Boehringer-Mannheim).After pre-hybridizing the filter at 37° C. for 1 hour, theaforementioned probe labeled with digoxinigen was added followed byhybridizing at 37° C. for 16 hours. Subsequently, the filter was washedtwice at 60° C. with 1×SSC containing 0.1% SDS.

Detection of colonies that hybridized with the labeled probe was carriedout based on the manual using the DIG Nucleotide Detection Kit(manufactured by Boehringer-Mannheim). As a result, 1 strain of colonieswas confirmed to hybridize with the labeled probe.

(5) Base Sequence of Peptide-Forming Enzyme Gene Derived fromPsycloserpens burtonensis Strain ATCC 700359

Plasmids retained by Escherichia coli JM109 were prepared from theaforementioned strain of microbial cells which were confirmed tohybridize with the labeled probe, and the nearby base sequence thathybridized with the probe was determined. The sequencing reaction wascarried out using the CEQ DTCS-Quick Start Kit (manufactured byBeckman-Coulter) based on the procedure described in the manual. Inaddition, electrophoresis was carried out using the CEQ 2000-XL(manufactured by Beckman-Coulter).

As a result, an open reading frame that encodes peptide-forming enzymewas found to exist. The base sequence of the full-length peptide-formingenzyme gene derived from Psycloserpens burtonensis strain ATCC 700359(Depositary institution: American Type Culture Collection, Address ofdepositary institution: P.O. Box 1549, Manassas, Va. 20110, the UnitedStates of America), along with the corresponding amino acid sequence,are shown in SEQ ID NO: 26 of the Sequence Listing.

INDUSTRIAL APPLICABILITY

According to the present invention, a novel enzyme is provided that canproduce a peptide easily, at high yield and inexpensively by reducingcomplex synthetic methods such as introduction and elimination ofprotecting groups. The use of the enzyme of the present inventionenables efficient industrial production of a peptide.

SEQUENCE LISTING

SEQ ID NO: 3: Synthetic primer 1SEQ ID NO: 4: Synthetic primer 2SEQ ID NO: 5: Gene encoding a peptide-forming enzymeSEQ ID NO: 7: Synthetic primer for preparing pTrpTSEQ ID NO: 8: Synthetic primer for preparing pTrpT

SEQ ID NO: 9: Synthetic primer for preparing pTrpT_Gtg2

SEQ ID NO: 10: Synthetic primer for preparing pTrpT_Gtg2SEQ ID NO: 11: Gene encoding peptide-forming enzymeSEQ ID NO: 13: Synthetic primer for preparing pTrpT_Sm_aetSEQ ID NO: 14: Synthetic primer for preparing pTrpT_Sm_aetSEQ ID NO: 15: Mix primer 1 for AetSEQ ID NO: 16: Mix primer 2 for AetSEQ ID NO: 19: Primer 1 for constructing aet expression vectors derivedfrom Pedobacter.SEQ ID NO: 20: Primer 2 for constructing aet expression vectors derivedfrom Pedobacter.SEQ ID NO: 21: Mix primer 3 for Aet

What we claim is:
 1. An isolated DNA encoding a protein selected fromthe group consisting of (K), (L), (W), and (X), wherein said protein hasan amino acid sequence defined as follows: (K) the amino acid sequenceconsisting of amino acid residues numbers 18 to 644 of SEQ ID NO:27, (L)an amino acid sequence which includes substitution, deletion, insertion,and/or addition, of one to 30 amino acids in the amino acid sequenceconsisting of amino acid residues numbers 18 to 644 of SEQ ID NO:27, andhas at least 50% of the peptide-forming activity of a proteincorresponding to unmutated amino acid residue numbers 18 to 644 of SEQID NO:27 at 50° C. and a pH of 8, (W) the amino acid sequence consistingof SEQ ID NO:27, and (X) an amino acid sequence which includessubstitution, deletion, insertion, and/or addition, of one to 30 aminoacids in the amino acid sequence consisting of SEQ ID NO:27, and has atleast 50% of the peptide-forming activity of a protein corresponding tounmutated SEQ ID NO:27 at 50° C. and a pH of 8, or an isolated DNAselected from the group consisting of (k), (k2), and (w), wherein saidDNA has a nucleotide sequence defined as follows: (k) a nucleotidesequence consisting of nucleotide numbers 104 to 1888 of SEQ ID NO:26,(k2) a nucleotide sequence that hybridizes under stringent conditionswith a DNA having a nucleotide sequence complementary to a nucleotidesequence consisting of nucleotide numbers 112 to 1992 of SEQ ID NO:26under stringent conditions, wherein said stringent conditions are0.1×SSC and 0.1% SDS at 65° C., and encodes a protein that has at least50% of the peptide-forming activity at 50° C. and a pH of 8 of a proteinencoded by unmutatetd nucleotide numbers 112 to 1992 of SEQ ID NO:26,(w) a nucleotide sequence consisting of nucleotide numbers 29 to 1888 ofSEQ ID NO:26.
 2. The isolated DNA of claim 1, wherein said DNA encodes aprotein having an amino acid sequence defined as follows: (K) the aminoacid sequence consisting of amino acid residues numbers 18 to 644 of SEQID NO:27, or (W) the amino acid sequence consisting of SEQ ID NO:27. 3.The isolated DNA of claim 1, wherein, in the protein of (L) and (X) thenumber of substitution, deletion, insertion and/or addition is 1 to 10amino acid residues.
 4. The isolated DNA of claim 1, wherein said DNAhas a nucleotide sequence defined as follows: (k) a nucleotide sequenceconsisting of nucleotide numbers 104 to 1888 of SEQ ID NO:26, or (w) anucleotide sequence consisting of nucleotide numbers 29 to 1888 of SEQID NO:26.
 5. A recombinant DNA comprising the DNA according to claim 1.6. A transformed cell comprising the recombinant DNA according to claim5.
 7. A method for producing a peptide-forming enzyme comprising:culturing the transformed cell according to claim 6 in a medium for atime and under conditions suitable to produce the peptide-formingenzyme, and accumulating the peptide-forming enzyme in the medium and/ortransformed cell.
 8. A method for producing a dipeptide comprising:culturing the transformed cell according to claim 6 in a medium for atime and under conditions suitable to produce a peptide-forming enzymein a culture, and mixing the culture with a carboxy component and anamine component to synthesize a dipeptide by enzymatic catalysisfacilitated by a peptide-forming enzyme encoded by said DNA; whereinsaid carboxy component is an amino acid ester or an amino acid amide;and wherein said amine component is selected from the group consistingof an amino acid and a C-protected amino acid.
 9. The method forproducing a dipeptide according to claim 8, wherein said transformedcell is a microbe belonging to the genus Escherichia that has an abilityto form the dipeptide from the carboxy component and the aminecomponent.
 10. A method for producing a dipeptide comprising: culturingthe transformed cell according to claim 6 in a medium for a time andunder conditions suitable to produce a peptide-forming enzyme,recovering said transformed cell from said culture, and mixing therecovered transformed cell with a carboxy component and an aminecomponent to synthesize a dipeptide by enzymatic catalysis facilitatedby a peptide-forming enzyme encoded by said DNA; wherein said carboxycomponent is an amino acid ester or an amino acid amide; and whereinsaid amine component is selected from the group consisting of an aminoacid and a C-protected amino acid.
 11. A method for producing adipeptide comprising: culturing the transformed cell according to claim6 in a medium for a time and under conditions suitable to produce apeptide-forming enzyme; recovering said transformed cell from saidculture; treating said transformed cell to produce a microbial cellproduct wherein said treating is selected from the group consisting ofacetone treating, freeze-drying, disrupting, and lysing; and mixing saidmicrobial cell product with a carboxy component and an amine componentto synthesize a dipeptide by enzymatic catalysis facilitated by apeptide-forming enzyme encoded by said DNA; wherein said carboxycomponent is an amino acid ester or an amino acid amide; and whereinsaid amine component is selected from the group consisting of an aminoacid and a C-protected amino acid.